Details of Drug-Metabolizing Enzyme (DME)

General Information of DME (ID: DME0019)
DME Name Cytochrome P450 2C9 (CYP2C9), Homo sapiens
Synonyms Cytochrome P450 family 2 subfamily C member 9; (R)-limonene 6-monooxygenase; (S)-limonene 6-monooxygenase; (S)-limonene 7-monooxygenase; Cytochrome P-450MP; Cytochrome P450 MP-4; Cytochrome P450 MP-8; Cytochrome P450 PB-1; CYP2C10; CYP2C9; CYPIIC9
Gene Name CYP2C9
UniProt ID
CP2C9_HUMAN
Gene ID
1559
EC Number    EC: 1.14.14.1     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.1
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
(loading-time for this interactome depdends on the speed of web connection)
       Interactions between Microbiome and DME (MICBIO)                       
Jump to Detailed Interactome Data                      
       Interactions between Xenobiotics and DME (XEOTIC)                      
Jump to Detailed Interactome Data                      
       Interactions between Host Protein and DME (HOSPPI)                     
Jump to Detailed Interactome Data                      
      Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME
Sequence
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV
Structure
1R9O ; 4NZ2 ; 5A5I ; 5A5J ; 5K7K ; 5W0C ; 5X23 ; 5X24 ; 5XXI
Pathway Arachidonic acid metabolism (hsa00590 )
Chemical carcinogenesis (hsa05204 )
Drug metabolism - cytochrome P450 (hsa00982 )
Linoleic acid metabolism (hsa00591 )
Metabolic pathways (hsa01100 )
Metabolism of xenobiotics by cytochrome P450 (hsa00980 )
Retinol metabolism (hsa00830 )
Serotonergic synapse (hsa04726 )
Function This enzyme is involved in the metabolism of various endogenous substrates, including fatty acids and steroids. It catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) and hydroxylation of carbon-hydrogen bonds.It metabolizes cholesterol toward 25-hydroxycholesterol and catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA). It also metabolizes plant monoterpenes such as limonene; oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol and metabolizes drugs such as S- warfarin, diclofenac, phenytoin, tolbutamide and losartan.
Full List of Drug(s) Metabolized by This DME
      Drugs Approved by FDA Click to Show/Hide the Full List of Drugs:      223 Drugs
Thalidomide
 Drug Info Approved Breast cancer ICD11: 2C60 [1]
Bupropion
 Drug Info Approved Nicotine dependence ICD11: 6C4A [2]
Tamoxifen citrate
 Drug Info Approved Breast cancer ICD11: 2C60 [3]
Yn-968D1
 Drug Info Approved Breast cancer ICD11: 2C60-2C6Y [4]
Alosetron hydrochloride
 Drug Info Approved Irritable bowel syndrome ICD11: DD91 [5]
Idelalisib
 Drug Info Approved Chronic lymphocytic leukaemia ICD11: 2A82 [6]
Warfarin sodium
 Drug Info Approved Atrial fibrillation ICD11: BC81 [7]
Estradiol acetate
 Drug Info Approved Acquired prion disease ICD11: 8E01 [8]
Estradiol cypionate
 Drug Info Approved Acquired prion disease ICD11: 8E01 [8]
Estradiol valerate
 Drug Info Approved Acquired prion disease ICD11: 8E01 [8]
Estrone
 Drug Info Approved Menopausal disorder ICD11: GA30 [8]
Nicotine
 Drug Info Approved Nicotine dependence ICD11: 6C4A [9]
Atazanavir
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [10]
Nabumetone
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [11]
Dronabinol
 Drug Info Approved Anorexia nervosa ICD11: 6B80 [12]
Bortezomib
 Drug Info Approved Breast cancer ICD11: 2C60 [13]
Diclofenac sodium
 Drug Info Approved Osteoarthritis ICD11: FA00 [14]
Fospropofol disodium
 Drug Info Approved Monitored anaesthesia care ICD11: N.A. [15]
Montelukast sodium
 Drug Info Approved Asthma ICD11: CA23 [16]
Progesterone
 Drug Info Approved Premature labour ICD11: JB00 [17]
Rosiglitazone
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [18]
Rosiglitazone
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [19]
Rosiglitazone
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [20]
Imatinib mesylate
 Drug Info Approved Chronic myelogenous leukaemia ICD11: 2A20 [21]
Lidocaine
 Drug Info Approved Anaesthesia ICD11: 8E22 [22]
Metronidazole
 Drug Info Approved Amebiasis ICD11: 1A36 [22]
Valdecoxib
 Drug Info Approved Osteoarthritis ICD11: FA00 [23]
Brivaracetam
 Drug Info Approved Focal seizure ICD11: 8A68 [24]
Cannabidiol
 Drug Info Approved Lennox-Gastaut syndrome ICD11: 8A62 [25]
Capsaicin
 Drug Info Approved Herpes zoster ICD11: 1E91 [26]
Doxazosin
 Drug Info Approved Essential hypertension ICD11: BA00 [27]
Ethinyl estradiol
 Drug Info Approved Menopausal disorder ICD11: GA30 [28]
Ifosfamide
 Drug Info Approved Lung cancer ICD11: 2C25 [29]
Irbesartan
 Drug Info Approved Essential hypertension ICD11: BA00 [30]
Lapatinib ditosylate
 Drug Info Approved Breast cancer ICD11: 2C60 [31]
Pitavastatin
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [32]
Pitavastatin
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [33], [34]
Siponimod
 Drug Info Approved Multiple sclerosis ICD11: 8A40 [35]
Terbinafine hydrochloride
 Drug Info Approved Pityriasis versicolor ICD11: 1F2D [36]
Tretinoin
 Drug Info Approved Acne vulgaris ICD11: ED80 [22]
Valproic acid
 Drug Info Approved Epilepsy ICD11: 8A60 [37]
Duloxetine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [38]
Enzalutamide
 Drug Info Approved Prostate cancer ICD11: 2C82 [39]
Febuxostat
 Drug Info Approved Hyperuricaemia ICD11: 5C55 [40]
Norethindrone
 Drug Info Approved Solid tumour/cancer ICD11: 2A00-2F9Z [41]
Pioglitazone hydrochloride
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [42]
Pravastatin
 Drug Info Approved Dyslipidaemia ICD11: 5C81 [43]
Trabectedin
 Drug Info Approved Leiomyosarcoma ICD11: 2B58 [44]
Dopamine hydrochloride
 Drug Info Approved Parkinsonism ICD11: 8A00 [45]
Halothane
 Drug Info Approved Anaesthesia ICD11: 8E22 [46]
Ketamine
 Drug Info Approved Anaesthesia ICD11: 8E22 [47]
Ketorolac
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [48]
Quinine sulfate
 Drug Info Approved Malaria ICD11: 1F40 [49]
Suprofen
 Drug Info Approved Iris sphincter disorder ICD11: 9B01 [50]
Alitretinoin
 Drug Info Approved Kaposi sarcoma ICD11: 2B57 [51]
Caffeine
 Drug Info Approved Orthostatic hypotension ICD11: BA21 [52]
Carvedilol
 Drug Info Approved Congestive heart failure ICD11: BD10 [53]
Cisapride
 Drug Info Approved Gastro-oesophageal reflux disease ICD11: DA22 [54]
Dextromethorphan hydrobromide
 Drug Info Approved Atherosclerosis ICD11: BA80 [55]
Diazepam
 Drug Info Approved Epilepsy ICD11: 8A60 [56]
Doxepin hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [57]
Formoterol
 Drug Info Approved Asthma ICD11: CA23 [58]
Haloperidol decanoate
 Drug Info Approved Agitation/aggression ICD11: 6D86 [59]
Ketoprofen
 Drug Info Approved Anaesthesia ICD11: 8E22 [60]
Lansoprazole
 Drug Info Approved Duodenal ulcer ICD11: DA63 [36]
Levonorgestrel
 Drug Info Approved Menorrhagia ICD11: GA20 [61]
Macitentan
 Drug Info Approved Pulmonary hypertension ICD11: BB01 [62]
Naproxen
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [63]
Nateglinide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [64]
Nevirapine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [65]
Ondansetron
 Drug Info Approved Gastritis ICD11: DA42 [22]
Phenylbutazone
 Drug Info Approved Anaesthesia ICD11: 8E22 [66]
Rofecoxib
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [67]
Trimethoprim
 Drug Info Approved Infectious cystitis ICD11: GC00 [68]
Verapamil hydrochloride
 Drug Info Approved Essential hypertension ICD11: BA00 [69]
Amitriptyline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [70]
Amprenavir
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [71]
Artemether
 Drug Info Approved Malaria ICD11: 1F40 [72]
Avanafil
 Drug Info Approved Erectile dysfunction ICD11: HA01 [73]
Belinostat
 Drug Info Approved Anaplastic large cell lymphoma ICD11: 2A90 [74]
Bromfenac
 Drug Info Approved Cataract ICD11: 9B10 [75]
Cyclophosphamide
 Drug Info Approved Multiple myeloma ICD11: 2A83 [29]
Diltiazem hydrochloride
 Drug Info Approved Essential hypertension ICD11: BA00 [69]
Donepezil hydrochloride
 Drug Info Approved Alzheimer disease ICD11: 8A20 [76]
Erdafitinib
 Drug Info Approved Renal cell carcinoma ICD11: 2C90 [77]
Etodolac
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [78]
Fluoxetine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [79]
Fluvastatin sodium
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [80]
Histamine
 Drug Info Approved Allergy ICD11: 4A80 [10]
Ibuprofen
 Drug Info Approved Anaesthesia ICD11: 8E22 [22]
Indomethacin
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [36]
Isotretinoin
 Drug Info Approved Acne vulgaris ICD11: ED80 [81]
Istradefylline
 Drug Info Approved Parkinsonism ICD11: 8A00 [82]
Leflunomide
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [83]
Lesinurad
 Drug Info Approved Uncontrolled gout ICD11: FA25 [84]
Oxaprozin
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [85]
Phenytoin
 Drug Info Approved Epilepsy ICD11: 8A60 [86]
Promazine
 Drug Info Approved Schizophrenia ICD11: 6A20 [87]
Quinidine
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [88]
Simvastatin
 Drug Info Approved Dyslipidaemia ICD11: 5C81 [89]
Tapentadol
 Drug Info Approved Neuropathic pain ICD11: 8E43 [90]
Vismodegib
 Drug Info Approved Melanoma ICD11: 2C30 [91]
Zileuton
 Drug Info Approved Asthma ICD11: CA23 [92]
Zolpidem tartrate
 Drug Info Approved Insomnia ICD11: 7A00 [93]
Amiodarone hydrochloride
 Drug Info Approved Ventricular tachyarrhythmia ICD11: BC71 [36]
Aspirin
 Drug Info Approved Myocardial infarction ICD11: BA41 [94]
Azelastine
 Drug Info Approved Allergic rhinitis ICD11: CA08 [95]
Buprenorphine hydrochloride
 Drug Info Approved Anaesthesia ICD11: 8E22 [36]
Cabozantinib
 Drug Info Approved Thyroid cancer ICD11: 2D10 [96]
Chlorpropamide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [97]
Clozapine
 Drug Info Approved Schizophrenia ICD11: 6A20 [98]
Diphenhydramine
 Drug Info Approved Meniere disease ICD11: AB31 [99]
Dolasetron mesylate
 Drug Info Approved Functional nausea/vomiting ICD11: DD90 [22]
Eszopiclone
 Drug Info Approved Insomnia ICD11: 7A00 [87]
Etravirine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [100]
Fosphenytoin sodium
 Drug Info Approved Epilepsy ICD11: 8A60 [36]
Glipizide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [101]
Mirtazapine
 Drug Info Approved Depression ICD11: 6A71 [22]
Nalbuphine
 Drug Info Approved Pain ICD11: MG30-MG3Z [102]
Omeprazole
 Drug Info Approved Gastro-oesophageal reflux disease ICD11: DA22 [103]
Ospemifene
 Drug Info Approved Dyspareunia ICD11: GA12 [104]
Pentobarbital
 Drug Info Approved Insomnia ICD11: 7A00 [105]
Perphenazine
 Drug Info Approved Schizophrenia ICD11: 6A20 [106]
Phenprocoumon
 Drug Info Approved Thrombosis ICD11: DB61 [107]
Propofol
 Drug Info Approved Anaesthesia ICD11: 8E22 [108]
Sulfamethoxazole
 Drug Info Approved Infectious cystitis ICD11: GC00 [109]
Tasimelteon
 Drug Info Approved Insomnia ICD11: 7A00 [110]
Testosterone undecanoate
 Drug Info Approved Hypogonadism ICD11: 5A61 [111]
Tolazamide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [112]
Torasemide
 Drug Info Approved Congestive heart failure ICD11: BD10 [36]
Treprostinil
 Drug Info Approved Pulmonary hypertension ICD11: BB01 [113]
Venlafaxine hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [114]
Vortioxetine hydrobromide
 Drug Info Approved Depression ICD11: 6A71 [115]
Zafirlukast
 Drug Info Approved Asthma ICD11: CA23 [116]
Acetaminophen
 Drug Info Approved Anaesthesia ICD11: 8E22 [22]
Acetohexamide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [112]
Alprazolam
 Drug Info Approved Anxiety disorder ICD11: 6B00 [36]
Apixaban
 Drug Info Approved Deep vein thrombosis ICD11: BD71 [117]
Avapritinib
 Drug Info Approved Gastrointestinal stromal tumour ICD11: 2B5B [118]
Avapritinib
 Drug Info Approved Gastrointestinal stromal tumour ICD11: 2B5B [119]
Binimetinib
 Drug Info Approved Melanoma ICD11: 2C30 [120]
Candesartan cilexetil
 Drug Info Approved Essential hypertension ICD11: BA00 [121]
Dapagliflozin
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [122]
Dicumarol
 Drug Info Approved Menorrhagia ICD11: GA20 [123]
Levomethadyl acetate hydrochloride
 Drug Info Approved Opiate dependence ICD11: 6C43 [124]
Losartan potassium
 Drug Info Approved Essential hypertension ICD11: BA00 [36]
Lovastatin
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [125]
Methadone
 Drug Info Approved Anaesthesia ICD11: 8E22 [126]
Phenobarbital
 Drug Info Approved Epilepsy ICD11: 8A60 [127]
Piroxicam
 Drug Info Approved Anaesthesia ICD11: 8E22 [128]
Pitavastatin calcium
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [129]
Ruxolitinib
 Drug Info Approved Chronic myelogenous leukaemia ICD11: 2A20 [130]
Ruxolitinib
 Drug Info Approved Chronic myelogenous leukaemia ICD11: 2A20 [131]
Ruxolitinib phosphate
 Drug Info Approved Myelofibrosis ICD11: 2A22 [130]
Sulfadiazine
 Drug Info Approved Toxoplasmosis ICD11: 1F57 [132]
Tapinarof
 Drug Info Approved Discovery agent ICD: N.A. [133]
Timolol maleate
 Drug Info Approved Essential hypertension ICD11: BA00 [134]
Tolbutamide
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [135]
Tolterodine tartrate
 Drug Info Approved Overactive bladder ICD11: GC50 [136]
Troglitazone
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [137]
Voriconazole
 Drug Info Approved Candidiasis ICD11: 1F23 [138]
Zidovudine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [22]
Azilsartan
 Drug Info Approved Hypertension ICD11: BA00-BA04 [139]
Azilsartan
 Drug Info Approved Hypertension ICD11: BA00-BA04 [140], [141]
Azilsartan medoxomil
 Drug Info Approved Essential hypertension ICD11: BA00 [142]
Bosentan
 Drug Info Approved Pulmonary hypertension ICD11: BB01 [143]
Celecoxib
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [63]
Clofibrate
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [144]
Clopidogrel bisulfate
 Drug Info Approved Acute coronary syndrome ICD11: BA4Z [145]
Dapsone
 Drug Info Approved Pneumocystis pneumonia ICD11: CA40 [146]
Eletriptan hydrobromide
 Drug Info Approved Migraine ICD11: 8A80 [147]
Epoprostenol
 Drug Info Approved Pulmonary hypertension ICD11: BB01 [148]
Fenoprofen
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [149]
Fenoprofen
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [150]
Flibanserin
 Drug Info Approved Inhibited sexual desire ICD11: HA00 [151]
Fluconazole
 Drug Info Approved Candidiasis ICD11: 1F23 [152]
Flurbiprofen sodium
 Drug Info Approved Rheumatoid arthritis ICD11: FA20 [153]
Hydromorphone
 Drug Info Approved Anaesthesia ICD11: 8E22 [154]
Iclaprim
 Drug Info Approved Methicillin-resistant staphylococcus infection ICD11: 1D01 [155]
Lacosamide
 Drug Info Approved Epilepsy ICD11: 8A60 [156]
Loratadine
 Drug Info Approved Allergic rhinitis ICD11: CA08 [157]
Mefenamic acid
 Drug Info Approved Female pelvic pain ICD11: GA34 [158]
Mephenytoin
 Drug Info Approved Epilepsy ICD11: 8A60 [159]
Niclosamide
 Drug Info Approved Tapeworm infestation ICD11: 1F7Y [160]
Prasugrel hydrochloride
 Drug Info Approved Acute coronary syndrome ICD11: BA4Z [161]
Primidone
 Drug Info Approved Epilepsy ICD11: 8A60 [162]
Quazepam
 Drug Info Approved Insomnia ICD11: 7A00 [163]
Rosuvastatin
 Drug Info Approved Hypertriglyceridaemia ICD11: 5C80 [164]
Selegiline hydrochloride
 Drug Info Approved Parkinsonism ICD11: 8A00 [22]
Sertraline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [165]
Sildenafil citrate
 Drug Info Approved Erectile dysfunction ICD11: HA01 [36]
Temazepam
 Drug Info Approved Insomnia ICD11: 7A00 [166]
Triclabendazole
 Drug Info Approved Fascioliasis ICD11: 1F82 [167]
Trimipramine
 Drug Info Approved Depression ICD11: 6A71 [168]
Voxelotor
 Drug Info Approved Sickle-cell anaemia ICD11: 3A51 [169]
Ampiroxicam
 Drug Info Approved Inflammation ICD11: 1A00-CA43 [170]
Bexarotene
 Drug Info Approved Anaplastic large cell lymphoma ICD11: 2A90 [22]
Dacomitinib
 Drug Info Approved Lung cancer ICD11: 2C25 [171]
Dorzolamide hydrochloride
 Drug Info Approved Glaucoma ICD11: 9C61 [22]
Enasidenib
 Drug Info Approved Acute myeloid leukaemia ICD11: 2A60 [172]
Glimepiride
 Drug Info Approved Diabetes mellitus ICD11: 5A10 [173]
Idarubicin
 Drug Info Approved Acute myeloid leukaemia ICD11: 2A60 [174]
Meloxicam
 Drug Info Approved Osteoarthritis ICD11: FA00 [22]
Nortriptyline hydrochloride
 Drug Info Approved Depression ICD11: 6A71 [36]
Olodaterol hydrochloride
 Drug Info Approved Chronic obstructive pulmonary disease ICD11: CA22 [175]
Paramethadione
 Drug Info Approved Embryofetopathy ICD11: LD2F [176]
Rifampicin
 Drug Info Approved Osteoporosis ICD11: FB83 [36]
Rimegepant
 Drug Info Approved Migraine ICD11: 8A80 [177]
Rimegepant
 Drug Info Approved Migraine ICD11: 8A80 [178]
Sevoflurane
 Drug Info Approved Anaesthesia ICD11: 8E22 [179]
Testosterone cypionate
 Drug Info Approved Testosterone deficiency ICD11: 5A81 [111]
Testosterone enanthate
 Drug Info Approved Testosterone deficiency ICD11: 5A81 [111]
Trimethadione
 Drug Info Approved Epilepsy ICD11: 8A60 [180]
Valsartan
 Drug Info Approved Essential hypertension ICD11: BA00 [181]
Zalcitabine
 Drug Info Approved Human immunodeficiency virus infection ICD11: 1C60 [182]
Avatrombopag maleate
 Drug Info Approved Thrombocytopenia ICD11: 3B64 [183]
Methoxyflurane
 Drug Info Approved Anaesthesia ICD11: 8E22 [184]
Nabilone
 Drug Info Approved Insomnia ICD11: 7A00-7A0Z [185]
Testosterone
 Drug Info Approved Osteoporosis ICD11: FB83 [186]
Trifarotene
 Drug Info Approved Acne vulgaris ICD11: ED80 [187]
Umbralisib
 Drug Info Approved Follicular lymphoma ICD11: 2A80 [188]
LAROPIPRANT
 Drug Info Phase 4 Atherosclerosis ICD11: BA80 [197]
Neupro
 Drug Info Phase 4 Restless legs syndrome ICD11: 7A80 [199]
      Drugs in Phase 4 Clinical Trial Click to Show/Hide the Full List of Drugs:        40 Drugs
Lumiracoxib
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [189]
Ethinylestradiol propanesulfonate
 Drug Info Phase 4 Prostate cancer ICD11: 2C82 [190], [191]
Desogestrel
 Drug Info Phase 4 Female pelvic pain ICD11: GA34 [192]
Parecoxib
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [193]
Mestranol
 Drug Info Phase 4 Menorrhagia ICD11: GA20 [36]
Benzbromarone
 Drug Info Phase 4 Hyperuricaemia ICD11: 5C55 [194]
Cinnarizine
 Drug Info Phase 4 Haemorrhagic stroke ICD11: 8B20 [36]
Glibenclamide
 Drug Info Phase 4 Diabetes mellitus ICD11: 5A10 [195]
Ketobemidone
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [196]
Naftopidil
 Drug Info Phase 4 Prostatic hyperplasia ICD11: GA90 [198]
Piperaquine
 Drug Info Phase 4 Malaria ICD11: 1F40 [200]
Melatonin
 Drug Info Phase 4 Foetal growth restriction ICD11: KA20 [14]
Tropisetron
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [22]
Vonoprazan
 Drug Info Phase 4 Gastro-oesophageal reflux disease ICD11: DA22 [201]
Aceclofenac
 Drug Info Phase 4 Rheumatoid arthritis ICD11: FA20 [202]
Etoricoxib
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [203]
Idebenone
 Drug Info Phase 4 Mitochondrial myopathy ICD11: 8C73 [204]
Imrecoxib
 Drug Info Phase 4 Osteoarthritis ICD11: FA00 [205]
Phenacetin
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [206]
Terfenadine
 Drug Info Phase 4 Allergy ICD11: 4A80 [207]
Tienilic acid
 Drug Info Phase 4 Congestive heart failure ICD11: BD10 [208]
Tranilast
 Drug Info Phase 4 Conjunctivitis ICD11: 9A60 [209]
Aminophenazone
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [36]
Flunarizine
 Drug Info Phase 4 Schizophrenia ICD11: 6A20 [144]
Flunitrazepam
 Drug Info Phase 4 Insomnia ICD11: 7A00 [210]
Gliclazide
 Drug Info Phase 4 Diabetes mellitus ICD11: 5A10 [36]
Lynestrenol
 Drug Info Phase 4 Transsexualism ICD11: HA60 [41]
Perazine
 Drug Info Phase 4 Cerebrovascular dementia ICD11: 6D81 [211]
Zaltoprofen
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [36]
Zopiclone
 Drug Info Phase 4 Insomnia ICD11: 7A00 [212]
Dexibuprofen
 Drug Info Phase 4 Osteoarthritis ICD11: FA00 [14]
Flucloxacillin
 Drug Info Phase 4 Staphylococcus infection ICD11: 1B73 [213]
Proguanil
 Drug Info Phase 4 Malaria ICD11: 1F40 [22]
Rupatadine
 Drug Info Phase 4 Allergy ICD11: 4A80 [214]
Tenoxicam
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [215]
Ximelagatran
 Drug Info Phase 4 Coagulation defect ICD11: 3B10 [216]
Gliquidone
 Drug Info Phase 4 Diabetes mellitus ICD11: 5A10 [112]
Lornoxicam
 Drug Info Phase 4 Myocardial infarction ICD11: BA41 [217]
Sitaxentan
 Drug Info Phase 4 Pulmonary hypertension ICD11: BB01 [218]
Thiamylal
 Drug Info Phase 4 Anaesthesia ICD11: 8E22 [219]
      Drugs in Phase 3 Clinical Trial Click to Show/Hide the Full List of Drugs:        27 Drugs
PF-04965842
 Drug Info Phase 3 Atopic dermatitis ICD11: EA80 [220]
E-3A
 Drug Info Phase 3 Turner syndrome ICD11: LD50 [221]
Selumetinib
 Drug Info Phase 3 Neurofibromatosis ICD11: LD2D [222], [223]
BMS-298585
 Drug Info Phase 3 Diabetes mellitus ICD11: 5A10 [224]
BMS-650032
 Drug Info Phase 3 Viral hepatitis ICD11: 1E51 [225]
BAF-312
 Drug Info Phase 3 Multiple sclerosis ICD11: 8A40 [35]
Mavacamten
 Drug Info Phase 3 Hypertrophic cardiomyopathy ICD11: BC43 [226]
RO-111163
 Drug Info Phase 3 Hypersalivation ICD11: DA04 [22]
SCH-417690
 Drug Info Phase 3 Human immunodeficiency virus infection ICD11: 1C60 [36]
Alilusem
 Drug Info Phase 3 Essential hypertension ICD11: BA00 [227]
GW-1000
 Drug Info Phase 3 Cerebral vasospasm ICD11: BA85 [228]
Losartan
 Drug Info Phase 3 Hypertension ICD11: BA00-BA04 [229]
LY-450139
 Drug Info Phase 3 Alzheimer disease ICD11: 8A20 [230]
R-1124
 Drug Info Phase 3 Functional nausea/vomiting ICD11: DD90 [231]
SC-411
 Drug Info Phase 3 Alzheimer disease ICD11: 8A20 [232]
CR-2017
 Drug Info Phase 3 Irritable bowel syndrome ICD11: DD91 [233]
Esonarimod
 Drug Info Phase 3 Rheumatoid arthritis ICD11: FA20 [234]
Fenfluramine
 Drug Info Phase 3 Dravet syndrome ICD11: 8A61-8A6Z [235]
Imatinib
 Drug Info Phase 3 Mantle cell lymphoma ICD11: 2A85 [236]
TAK-491
 Drug Info Phase 3 Hypertension ICD11: BA00-BA04 [237]
JNJ-54135419
 Drug Info Phase 3 Depression ICD11: 6A71 [47]
MRTX849
 Drug Info Phase 3 Lung cancer ICD11: 2C25 [238]
Sildenafil
 Drug Info Phase 3 Erectile dysfunction ICD11: HA00-HA01 [239]
Ag-221
 Drug Info Phase 3 Acute myelogenous leukaemia ICD11: 2A41 [240]
Clazosentan
 Drug Info Phase 3 Cerebral vasospasm ICD11: BA85 [241]
CYT-387
 Drug Info Phase 3 Myelofibrosis ICD11: 2A22 [242]
Montelukast
 Drug Info Phase 3 Asthma ICD11: CA23 [36]
      Drugs in Phase 2 Clinical Trial Click to Show/Hide the Full List of Drugs:        21 Drugs
Verapamil
 Drug Info Phase 2/3 Hypertension ICD11: BA00-BA04 [243]
EMD-128130
 Drug Info Phase 2/3 Rett syndrome ICD11: LD90 [244]
ANW-43703
 Drug Info Phase 2/3 Anogenital warts ICD11: 1A95 [245]
ONO-2506
 Drug Info Phase 2/3 Haemorrhagic stroke ICD11: 8B20 [246]
LIK-066
 Drug Info Phase 2 Heart failure ICD11: BD10-BD1Z [247]
LJN452
 Drug Info Phase 2 Primary biliary cholangitis ICD11: DB96 [248]
PT2385
 Drug Info Phase 2 Von hippel-lindau disease ICD11: 5A75 [249]
VATALANIB
 Drug Info Phase 2 Solid tumour/cancer ICD11: 2A00-2F9Z [250]
Remogliflozin etabonate
 Drug Info Phase 2 Type-1/2 diabetes ICD11: 5A10-5A11 [251]
S-777469
 Drug Info Phase 2 Atopic dermatitis ICD11: EA80 [252]
SSR-97193
 Drug Info Phase 2 Malaria ICD11: 1F40 [253]
HP-184
 Drug Info Phase 2 Multiple sclerosis ICD11: 8A40 [254]
J-005528
 Drug Info Phase 2 Infectious cystitis ICD11: GC00 [132]
Z-4828
 Drug Info Phase 2 Histiocytic sarcoma ICD11: 2B31 [255]
AZD2624
 Drug Info Phase 2 Multiple sclerosis ICD11: 8A40 [256]
BRN-0592109
 Drug Info Phase 2 Diabetes mellitus ICD11: 5A10 [112]
Dextofisopam
 Drug Info Phase 2 Irritable bowel syndrome ICD11: DD91 [257]
HPPH
 Drug Info Phase 2 Lung cancer ICD11: 2C25 [258]
Tarafenacin
 Drug Info Phase 2 Overactive bladder ICD11: GC50 [250]
E-7070
 Drug Info Phase 2 Breast cancer ICD11: 2C60 [259]
TAK-906
 Drug Info Phase 2 Gastroparesis ICD11: DA41 [260]
      Drugs in Phase 1 Clinical Trial Click to Show/Hide the Full List of Drugs:        12 Drugs
CB-3304
 Drug Info Phase 1/2 Chronic lymphocytic leukaemia ICD11: 2A82 [261]
CC-223
 Drug Info Phase 1/2 Lung cancer ICD11: 2C25 [262]
TRV-130
 Drug Info Phase 1/2 Hypothyroidism ICD11: 5A00 [263]
AG-1549
 Drug Info Phase 1 Human immunodeficiency virus infection ICD11: 1C60 [264]
STX 64
 Drug Info Phase 1 Prostate cancer ICD11: 2C82 [265]
BE-14348A
 Drug Info Phase 1 Viral hepatitis ICD11: 1E51 [266]
H3B-6545
 Drug Info Phase 1 Breast cancer ICD11: 2C60 [267]
GDC-0623
 Drug Info Phase 1 Solid tumour/cancer ICD11: 2A00-2F9Z [268]
MN-1695
 Drug Info Phase 1 Gastric ulcer ICD11: DA60 [269]
BZ-55
 Drug Info Phase 1 Diabetes mellitus ICD11: 5A10 [112]
G-23350
 Drug Info Phase 1 Venous thromboembolism ICD11: BD72 [217]
HSP-990
 Drug Info Phase 1 Breast cancer ICD11: 2C60 [270]
      Discontinued/withdrawn Drugs Click to Show/Hide the Full List of Drugs:        10 Drugs
Almokalant
 Drug Info Discontinued in Phase 3 Cardiac arrhythmias ICD11: BC9Z [271]
KRP-297
 Drug Info Discontinued in Phase 2 Hypertriglyceridaemia ICD11: 5C80 [272]
Tetramethylpyrazine
 Drug Info Discontinued in Phase 2 Neurological disorder ICD11: 6B60 [273]
BMS-181168
 Drug Info Discontinued in Phase 2 Cognitive impairment ICD11: 6D71 [274]
AZD0837
 Drug Info Discontinued in Phase 2 Atrial fibrillation ICD11: BC81 [275]
Tr-14035
 Drug Info Discontinued in Phase 1 Multiple sclerosis ICD11: 8A40 [276]
FCF-89
 Drug Info Discontinued Rheumatoid arthritis ICD11: FA20 [277], [278]
GV-150526
 Drug Info Discontinued Cerebral stroke ICD11: 8B11 [36]
ML-3000
 Drug Info Discontinued Osteoarthritis ICD11: FA00 [36]
ABT-001
 Drug Info Discontinued Asthma ICD11: CA23 [22]
      Preclinical/investigative Agents Click to Show/Hide the Full List of Drugs:          8 Drugs
EPX-100
 Drug Info Preclinical Dravet syndrome ICD11: 8A61 [279]
VA-10872
 Drug Info Preclinical Anaesthesia ICD11: 8E22 [22]
Coumarin
 Drug Info Investigative Discovery agent ICD: N.A. [7]
Arachidonic acid
 Drug Info Investigative Discovery agent ICD: N.A. [14]
Antipyrine
 Drug Info Investigative Discovery agent ICD: N.A. [36]
Estrone sulfate
 Drug Info Investigative Discovery agent ICD: N.A. [7]
Lauric acid
 Drug Info Investigative Alzheimer disease ICD11: 8A20 [280]
Cyamemazine
 Drug Info Investigative Discovery agent ICD: N.A. [281]
Full List of Metabolic Reactions (MR) Catalyzed by This DME
MR ID Reactant Product MR Type Source Drug REF
MR010130 (+)-JQ1 (+)-JQ1 Metabolite M1 Unclear - Unclear (+)-JQ1 [282]
MR010136 (+)-JQ1 (+)-JQ1 Metabolite M7 Unclear - Unclear (+)-JQ1 [282]
MR004533 ABT-001 ABT-001 Metabolite M- Other reaction - Methylhydroxylation ABT-001 [283], [284]
MR003371 Aceclofenac 4'-hydroxyaceclofenac Oxidation - 4'-Hydroxylation Aceclofenac [285]
MR003373 Aceclofenac 5-OH-aceclofenac Oxidation - Hydroxylation Aceclofenac [36]
MR012080 Alilusem MU2' Unclear - Unclear Alilusem [227]
MR002988 Alitretinoin 4-oxo-9-cis-retinoic acid Unclear - Unclear Alitretinoin [51]
MR002991 Alitretinoin 4-hydroxy-9-cis-retinoic acid Unclear - Unclear Alitretinoin [51]
MR009416 Almokalant Almokalant Metabolite M13 Oxidation - Sulfoxidation Almokalant [271]
MR009417 Almokalant Almokalant Metabolite M16 Unclear - Unclear Almokalant [271]
MR008910 Piroxicam 5'-Hydroxypiroxicam Unclear - Unclear Ampiroxicam [170]
MR000228 Amprenavir Amprenavir metabolite M2 Unclear - Unclear Amprenavir [286]
MR000227 Amprenavir Amprenavir metabolite M1 Unclear - Unclear Amprenavir [286]
MR007486 Antipyrine Norantipyrine Unclear - Unclear Antipyrine [36]
MR007488 Antipyrine 3-OH-methylantipyrine Oxidation - Hydrolyzationn Antipyrine [36]
MR006504 ANW-43703 Gentistic acid Oxidation - Aromatic hydroxylation ANW-43703 [245]
MR000248 Apixaban Apixaban M2 metabolite Oxidation - O-Demethylation Apixaban [117], [287]
MR000249 Apixaban Apixaban M4/7 metabolite Oxidation - Hydroxylation Apixaban [117], [287]
MR007489 Arachidonic acid EET Unclear - Unclear Arachidonic acid [288]
MR000298 Artemether Dihydroartemisinin Oxidation - Oxidation Artemether [289]
MR002995 Salicylic acid Gentistic acid Unclear - Unclear Aspirin [94]
MR009880 Avanafil Avanafil Metabolite M1 Unclear - Unclear Avanafil [290], [291]
MR009881 Avanafil Avanafil Metabolite M2 Unclear - Unclear Avanafil [290], [291]
MR009882 Avanafil Avanafil Metabolite M4-1 Unclear - Unclear Avanafil [290], [291]
MR009883 Avanafil Avanafil Metabolite M4-2 Unclear - Unclear Avanafil [290], [291]
MR009884 Avanafil Avanafil Metabolite M16 Unclear - Unclear Avanafil [290], [291]
MR005429 Avapritinib M690 Conjugation - Hydroxy glucuronidation Avapritinib [118]
MR011862 AZD0837 AR-H069927 Oxidation - Oxidation AZD0837 [275]
MR011562 AZD2624 AZD2624 Metabolite M1 Unclear - Unclear AZD2624 [256]
MR011563 AZD2624 AZD2624 Metabolite M2 Unclear - Unclear AZD2624 [256]
MR008918 Azilsartan Azilsartan M-II Oxidation - O-dealkylation Azilsartan [139], [141]
MR013087 Azilsartan Azilsartan M- Reduction - Decarboxylation Azilsartan medoxomil [142]
MR009614 BAF-312 Siponimod M7 Oxidation - Hydroxylation BAF-312 [35]
MR009616 BAF-312 Siponimod M6 Oxidation - Hydroxylation BAF-312 [35]
MR009618 BAF-312 Siponimod M5 Oxidation - Hydroxylation BAF-312 [35]
MR003839 BE-14348A Eriodictyol Oxidation - Hydrolyzationn BE-14348A [266]
MR003841 BE-14348A Apigenin Oxidation - Dehydrogenation BE-14348A [266]
MR003842 BE-14348A 5,7-Dihydroxychromone Unclear - Unclear BE-14348A [266]
MR006031 Belinostat Belinostat Amide Unclear - Unclear Belinostat [74]
MR006033 Belinostat Belinostat Acid Unclear - Unclear Belinostat [74]
MR003476 Benzbromarone Benzbromarone metabolite M7 Unclear - Unclear Benzbromarone [292]
MR003477 Benzbromarone Benzbromarone metabolite M6 Oxidation - Hydroxylation Benzbromarone [292]
MR010376 Benzoylphenylurea MmBPU Oxidation - Desmethylation Benzoylphenylurea [293], [294]
MR000372 Binimetinib 1,4-Diiminoquinone intermediate Oxidation - Two-Electron Oxidation Binimetinib [120]
MR000381 BMS-298585 BMS-298585 metabolite M10 Unclear - Unclear BMS-298585 [224], [295]
MR000378 BMS-298585 BMS-298585 metabolite M16 Unclear - Unclear BMS-298585 [224], [295]
MR000409 Bortezomib Bortezomib metabolite M2 Oxidation - Oxidation; Deboronation Bortezomib [36]
MR000452 BRN-1736748 Betaine Oxidation - Oxidation BRN-1736748 [296], [297]
MR000462 Bromfenac Bromfenac metabolite M1 Unclear - Unclear Bromfenac [75], [298]
MR000458 Bromfenac indolinone Bromfenac metabolite M3 Unclear - Unclear Bromfenac [75], [298]
MR000490 Buprenorphine hydrochloride Norbuprenorphine Oxidation - N-Dealkylation Buprenorphine hydrochloride [299]
MR000538 Cabozantinib EXEL-5162 Oxidation - N-Oxidation Cabozantinib [300]
MR000544 Caffeine 1,3,7-Trimethyluric acid Oxidation - 8-Hydroxylation Caffeine [301], [302]
MR000546 Caffeine Theophylline Oxidation - 7-N-Demethylation Caffeine [301], [302]
MR000553 Candesartan O-Deethylated candesartan Oxidation - O-Deethylation Candesartan cilexetil [36]
MR002512 Cannabidiol 7-hydroxy-cannabidiol Oxidation - Hydroxylation Cannabidiol [25]
MR002818 Capsaicin Capsaicin metabolite M1 Oxidation - Dehydrogenation Capsaicin [26]
MR002819 Capsaicin Capsaicin metabolite M2 Oxidation - Omega-Hydroxylation Capsaicin [26]
MR002820 Capsaicin Capsaicin metabolite M3 Oxidation - Omega-1-Hydroxylation Capsaicin [26]
MR002821 Capsaicin Capsaicin metabolite M4 Oxidation - Dehydrogenation Capsaicin [26]
MR002822 Capsaicin Capsaicin metabolite M5M7 Oxidation - Hydroxylation Capsaicin [26]
MR002823 Capsaicin Capsaicin metabolite M6 Oxidation - O-Dehydrogenation Capsaicin [26]
MR002824 Capsaicin Capsaicin metabolite M8 Oxidation - N-Dehydrogenation; Oxygenation Capsaicin [26]
MR002825 Capsaicin Capsaicin metabolite M9 Oxidation - N-Dehydrogenation Capsaicin [26]
MR000570 Carvedilol 4'-hydroxyphenylcarvedilol Oxidation - 4'-Hydroxylation Carvedilol [303]
MR000572 Carvedilol O-Desmethylcarvedilol Oxidation - O-Demethylation Carvedilol [303]
MR000571 Carvedilol 5'-hydroxyphenylcarvedilol Oxidation - 5'-Hydroxylation Carvedilol [303]
MR006091 CB-3304 CB-3304 Metabolite II Oxidation - Demethylation; cleavage CB-3304 [261]
MR006095 CC-223 O-desmethyl CC-223 Oxidation - N-demethylation CC-223 [262]
MR000587 Celecoxib Hydroxycelecoxib Oxidation - Hydroxylation Celecoxib [304]
MR002543 Chenodeoxycholic acid Chenodeoxycholic acid sulfolithocholyl metabolite Unclear - Unclear Chenodeoxycholic acid [305]
MR000650 Chlorpropamide 2-OH-chlorpropamide Oxidation - Hydroxylation Chlorpropamide [36]
MR000648 Chlorpropamide 2-hydroxychlorpropamide Oxidation - 2-Hydroxylation Chlorpropamide [36]
MR013303 Cinnarizine Cinnarizine metabolite M1 Unclear - Unclear Cinnarizine [36]
MR013306 Cinnarizine Cinnamaldehyde Oxidation - N-dealkylation Cinnarizine [306]
MR013307 Cinnarizine 1-Cinnamylpiperazine Oxidation - N-dealkylation; hydrolysis Cinnarizine [306]
MR006592 2-Oxoclopidogrel Active Metabolite of Clopidogrel spontaneous - spontaneous Clopidogrel bisulfate [36]
MR006591 Clopidogrel bisulfate 2-Oxoclopidogrel Oxidation - Oxidationn Clopidogrel bisulfate [36]
MR002835 Clozapine N-desmethylclozapine Oxidation - N-Demethylation Clozapine [36]
MR003080 CR-2017 O-demethyl dexloxiglumide Unclear - Unclear CR-2017 [307]
MR005318 Cyamemazine Cyamemazine sulfoxide Oxidation - Oxidationn Cyamemazine [308], [281]
MR012897 Cyclobenzaprine 4-Hydroxycyclophosphamide Oxidation - 4-hydroxylation Cyclobenzaprine [309], [36]
MR009942 Cyclophosphamide 4-Hydroxycyclophosphamide Unclear - Unclear Cyclophosphamide [310]
MR000716 Dacomitinib PF-05199265 Oxidation - O-Demethylation Dacomitinib [171], [311]
MR000733 Dapsone Dapsone hydroxylamine Oxidation - N-Hydroxylation Dapsone [36]
MR007087 Desogestrel 3alpha-OH-desogestrel Oxidation - Hydrolyzationn Desogestrel [36]
MR007090 Desogestrel 3beta-OH-desogestrel Oxidation - Hydrolyzationn Desogestrel [36]
MR012620 Dextofisopam Dextofisopam Metabolite M3 Unclear - Unclear Dextofisopam [257]
MR012619 Dextofisopam Metabolite M1 Dextofisopam Metabolite M5 Unclear - Unclear Dextofisopam [257]
MR000818 Dextromethorphan hydrobromide (+)-3-Methoxymorphinan Oxidation - N-Demethylation Dextromethorphan hydrobromide [312], [313]
MR000817 Dextromethorphan hydrobromide Dextrorphan Oxidation - O-Demethylation Dextromethorphan hydrobromide [312], [313]
MR000819 Diazepam Nordazepam Oxidation - N-Demethylation Diazepam [314], [315], [316]
MR000823 Temazepam Oxazepam Oxidation - N-Demethylation Diazepam [317], [316]
MR002600 3'-hydroxydiclofenac 3',4'-hydroxy diclofenac Oxidation - 4'-Hydroxylation Diclofenac sodium [318]
MR002606 5-hydroxy diclofenac 4',5-Dihydroxydiclofenac Oxidation - Hydroxylation Diclofenac sodium [319]
MR002614 Diclofenac sodium 5-hydroxy diclofenac Oxidation - 5-Hydroxylation Diclofenac sodium [319], [320]
MR002612 Diclofenac sodium 3'-hydroxydiclofenac Oxidation - 3'-Hydroxylation Diclofenac sodium [319], [320]
MR002613 Diclofenac sodium 4'-hydroxydiclofenac Oxidation - 4'-Hydroxylation Diclofenac sodium [321], [319], [320]
MR002616 Diclofenac sodium Diclofenac 2',3'-oxide Unclear - Unclear Diclofenac sodium [318]
MR000828 Dicumarol . Unclear - Unclear Dicumarol [123]
MR011193 Diphenhydramine N-Desmethyldiphenhydramine Unclear - Unclear Dimenhydrinate [36]
MR000876 Diphenhydramine N-desmethyldiphenhydramine Oxidation - N-Demethylation Diphenhydramine [322], [36], [323], [324]
MR000872 N-desmethyldiphenhydramine N,N-didesmethyldiphenhydramine Oxidation - N-Demethylation Diphenhydramine [322], [36], [323]
MR010554 Divalproex sodium 4-ene-VPA Unclear - Unclear Divalproex sodium [36]
MR006661 Doxepin hydrochloride N-desmethyldoxepin Oxidation - N-demethylation Doxepin hydrochloride [325]
MR006687 11-Hydroxy-delta-9-THC 11-Nor-9-carboxy-delta-9-THC Oxidation - Oxidationn Dronabinol [36]
MR006686 Dronabinol 11-Hydroxy-delta-9-THC Oxidation - 11-hydroxylation Dronabinol [36], [12], [326], [327]
MR006696 Dronabinol 11-OH-delata-Tetrahydrocannabinol Oxidation - Aliphatic hydroxylation Dronabinol [36], [328]
MR006715 Duloxetine hydrochloride 5-hydroxy duloxetine Oxidation - Hydrolyzationn Duloxetine hydrochloride [38]
MR006849 Eletriptan hydrobromide N-Desmethyl eletriptan Oxidation - N-demethylation Eletriptan hydrobromide [329]
MR006045 EMD-128130 Sarizotan metabolite M364A Oxidation - Hydrolyzationn EMD-128130 [244]
MR006867 Enasidenib AGI-16903 Oxidation - N-dealkylation Enasidenib [330]
MR006965 EPX-100 EPX-100 M2 Oxidation - Oxidationn EPX-100 [279]
MR006967 EPX-100 EPX-100 M19 Oxidation - Oxidationn EPX-100 [279]
MR006968 EPX-100 EPX-100 M14 Multi-steps Reaction - Oxidationn; conjugation EPX-100 [279]
MR012070 Deacetyl-esonarimod(M1) S-methyl-esonarimod(M2) Unclear - Unclear Esonarimod [234]
MR002696 Estrone 2-hydroxyestrone Oxidation - Hydroxylation Estrone [221]
MR002701 Estrone 4-OH-estrone Oxidation - Hydroxylation Estrone [331]
MR002721 Ethinyl estradiol 2-hydroxyethinylestradiol Oxidation - 2-Hydroxylation Ethinyl estradiol [332]
MR002722 Ethinyl estradiol 4-hydroxyethinylestradiol Oxidation - 4-Hydroxylation Ethinyl estradiol [332]
MR002723 Ethinyl estradiol 6-hydroxyethinylestradiol Oxidation - 6-Hydroxylation Ethinyl estradiol [332]
MR002724 Ethinyl estradiol 7-hydroxyethinylestradiol Oxidation - 7-Hydroxylation Ethinyl estradiol [332]
MR002725 Ethinyl estradiol 16alpha-hydroxyethinylestradiol Oxidation - 16-Hydroxylation Ethinyl estradiol [332]
MR014077 Ethinylestradiol propanesulfonate Unclear Oxidation - 16alpha-hydroxylation Ethinylestradiol propanesulfonate [190], [191]
MR002734 Etodolac 7-hydroxyetodolac Oxidation - 7-Hydroxylation Etodolac [87]
MR002735 Etodolac 6-hydroxyetodolac Oxidation - 6-Hydroxylation Etodolac [87]
MR002736 Etodolac 8-(1-hydroxyethyl)etodolac Oxidation - Hydroxylation Etodolac [333]
MR007168 6-Hydroxymethyletoricoxib 6-Hydroxymethyletoricoxib-1'-N'-oxide Oxidation - 1-N-oxidation Etoricoxib [36]
MR007166 6-Hydroxymethyletoricoxib 6-Carboxy-etoricoxib Oxidation - Oxidationn Etoricoxib [36]
MR007163 Etoricoxib Etoricoxib 1'-N'-oxide Oxidation - 1-N-oxidation Etoricoxib [36]
MR007165 Etoricoxib 6-Hydroxymethyletoricoxib Other reaction - 6-methylhydroxylation Etoricoxib [36]
MR007164 Etoricoxib 1'-N'-oxide 6-Hydroxymethyletoricoxib-1'-N'-oxide Other reaction - 6-methylhydroxylation Etoricoxib [334]
MR000986 Etravirine metabolite M1 Etravirine metabolite M5/6 Oxidation - Hydroxylation Etravirine [335]
MR000987 Etravirine metabolite M1 Etravirine metabolite M6/5 Oxidation - Hydroxylation Etravirine [335]
MR005969 FCF-89 PNU-212684 4-hydroxy-N-(4-hydroxyphenyl)-N,1-dimethyl-2-oxoquinoline-3-carboxamide Unclear - Unclear FCF-89 [277], [278]
MR003400 Febuxostat Febuxostat metabolite 67M-2 Oxidation - Oxidation Febuxostat [336]
MR003399 Febuxostat Febuxostat metabolite 67M-1 Oxidation - Oxidation Febuxostat [336]
MR012196 Fenfluramine Norfenfluramine Unclear - Unclear Fenfluramine [337]
MR007190 Flucloxacillin 5-hydroxymethyl-flucloxacillin Oxidation - Oxidationn Flucloxacillin [213]
MR013905 Flunarizine Flunarizine M1 Oxidation - N-desalkylation Flunarizine [36]
MR013907 Flunarizine Flunarizine M3 Oxidation - N-desalkylation Flunarizine [36]
MR005012 Fluoxetine hydrochloride Norfluoxetine Oxidation - N-demethylation Fluoxetine hydrochloride [325], [36], [338], [339]
MR005041 Flurbiprofen sodium 4'-Hydroxyflurbiprofen Oxidation - 4'-hydroxylation Flurbiprofen sodium [36], [340]
MR001063 Fluvastatin sodium 5-hydroxyfluvastatin Oxidation - 5-Hydroxylation Fluvastatin sodium [36], [341]
MR001065 Fluvastatin sodium 5-OH-fluvastatin Oxidation - Hydroxylation Fluvastatin sodium [36], [255], [342]
MR001061 Fluvastatin sodium 6-hydroxyfluvastatin Oxidation - 6-Hydroxylation Fluvastatin sodium [343]
MR001064 Fluvastatin sodium 6-OH-fluvastatin Oxidation - Hydroxylation Fluvastatin sodium [36], [255], [342]
MR002944 Formoterol O-demethylated formoterol Oxidation - O-demethylation Formoterol [344], [58]
MR003172 Phenytoin Phenytoin arene-oxide Oxidation - Oxidation Fosphenytoin sodium [325]
MR003261 Propofol 4-hydroxypropofol Oxidation - 4-Hydroxylation Fospropofol [36]
MR007835 Propofol 4-Hydroxypropofol Unclear - Unclear Fospropofol disodium [15]
MR009806 GDC-0623 GDC-0623 M14 Unclear - Unclear GDC-0623 [268]
MR009805 GDC-0623 M15 GDC-0623 M13 Unclear - Unclear GDC-0623 [268]
MR007218 Glibenclamide 2-trans-hydroxycyclohexyl glyburide Oxidation - Aliphatic hydroxylation Glibenclamide [345], [346]
MR007219 Glibenclamide 4-cis-hydroxycyclohexyl glyburide Oxidation - Aliphatic hydroxylation Glibenclamide [345], [346]
MR007220 Glibenclamide 3-trans-Hydroxycyclohexyl glyburide Oxidation - Aliphatic hydroxylation Glibenclamide [345], [346]
MR007221 Glibenclamide Ethylhydroxycyclohexyl glyburide Oxidation - Aliphatic hydroxylation Glibenclamide [345], [346]
MR007219 Glibenclamide 4-trans-hydroxycyclohexyl glyburide Oxidation - Aliphatic hydroxylation Glibenclamide [345], [346], [347]
MR007222 Glibenclamide 3-cis-Hydroxycyclohexyl glyburide Oxidation - Aliphatic hydroxylation Glibenclamide [345], [346], [347]
MR007223 Gliclazide Methylhydroxygliclazide Oxidation - Hydrolyzationn Gliclazide [36], [348]
MR007225 Gliclazide 7-OH-gliclazide Oxidation - Hydrolyzationn Gliclazide [36], [348]
MR007227 Gliclazide 6-OH-gliclazide Oxidation - Hydrolyzationn Gliclazide [36], [348]
MR001140 Glimepiride Cyclohexyl hydroxymethyl glimepiride Oxidation - Hydroxylation Glimepiride [36], [349]
MR001141 Glipizide 3-cis-hydroxyglipizide Oxidation - Hydroxylation Glipizide [36], [350]
MR001142 Glipizide 4-trans-hydroxyglipizide Oxidation - Hydroxylation Glipizide [36], [350]
MR001143 Glipizide 3-trans-hydroxyglipizide Oxidation - Hydroxylation Glipizide [350]
MR001144 Glipizide 4-trans-OH-glipizide Oxidation - Hydroxylation Glipizide [351]
MR007229 Gliquidone Unclear Unclear - Unclear Gliquidone [352]
MR005976 GV-150526 p-OH-gavestinel Oxidation - Aromatic hydroxylation GV-150526 [36]
MR005978 GV-150526 p-Hydroxygavestinel Oxidation - Hydrolyzationn GV-150526 [353]
MR005083 Halothane 2-chloro-1,1-difluoroethene Reduction - Dehalogenation Halothane [22], [328]
MR005084 Halothane 1-chloro-2,2,2-trifluoroethanide Reduction - Dehalogenation Halothane [22], [328]
MR012344 HPPH Catechol Unclear - Unclear HPPH [258]
MR005137 Hydromorphone Norhydromorphone Oxidation - N-demethylation Hydromorphone [154]
MR004642 3-Hydroxyibuprofen Carboxy-ibuprofen Oxidation - Dehydrogenation Ibuprofen [325], [36]
MR004644 Ibuprofen 2-Hydroxyibuprofen Oxidation - 2-hydroxylation Ibuprofen [36]
MR004641 Ibuprofen 3-Hydroxyibuprofen Oxidation - 3-hydroxylation Ibuprofen [36]
MR005774 Iclaprim Unclear Unclear - Unclear Iclaprim [155]
MR012970 GS-563117 Idelalisib Metabolite M19 Unclear - Unclear Idelalisib [6]
MR012964 Idelalisib Idelalisib Metabolite M2 Unclear - Unclear Idelalisib [6]
MR004650 Ifosfamide 4-Hydroxyifosfamide Oxidation - 4-hydroxylation Ifosfamide [309]
MR012008 Imatinib Other imatinib metabolites Unclear - Unclear Imatinib [354]
MR004669 Imatinib mesylate N-Desmethylimatinib Oxidation - N-demethylation Imatinib mesylate [36], [355], [356]
MR001200 Indomethacin 5-hydroxyindomethacin Oxidation - O-Demethylation Indomethacin [357]
MR001215 Irbesartan Irbesartan derivative M4 Oxidation - Hydroxylation Irbesartan [358], [36]
MR001216 Irbesartan Irbesartan derivative M5 Oxidation - Hydroxylation Irbesartan [358], [36]
MR001217 Irbesartan Irbesartan derivative M7 Oxidation - Hydroxylation Irbesartan [358], [36]
MR001212 Irbesartan derivative M5 Irbesartan derivative M1 Oxidation - Hydroxylation Irbesartan [36]
MR001213 Irbesartan derivative M7 Irbesartan derivative M1 Oxidation - Hydroxylation Irbesartan [36]
MR013337 JNJ-54135419 Noresketamine Oxidation - N-demethylation JNJ-54135419 [359]
MR001321 Ketamine Norketamine Oxidation - N-Demethylation Ketamine [47], [360], [361], [362]
MR001336 Ketobemidone Norketobemidone Oxidation - N-Demethylation Ketobemidone [36], [196]
MR001363 Ketoprofen 2-[3-(4-hydroxybenzoyl) phenyl]-propanoic acid Oxidation - Hydroxylation Ketoprofen [60], [363]
MR001364 Ketoprofen 2-[3-(3-hydroxybenzoyl) phenyl]-propanoic acid Oxidation - Hydroxylation Ketoprofen [60], [363]
MR001365 Ketoprofen 2-[3-(hydroxy(phenyl)methyl) phenyl]-propanoic acid Oxidation - Hydroxylation Ketoprofen [60], [363]
MR001368 Ketorolac 4-hydroxy ketorolac Oxidation - Hydroxylation Ketorolac [364]
MR012461 KLH-2109 KP046 Unclear - Unclear KLH-2109 [365]
MR012460 KLH-2109 KP017 Unclear - Unclear KLH-2109 [365]
MR011895 KRP-297 KRP-297 Metabolite M28 Unclear - Unclear KRP-297 [272]
MR001399 Lacosamide O-Desmethyl-lacosamide Oxidation - Demethylation Lacosamide [366]
MR009267 LAROPIPRANT LAROPIPRANT Metabolite M1 Oxidation - Monohydroxylation LAROPIPRANT [197]
MR009269 LAROPIPRANT LAROPIPRANT Metabolite M4 Oxidation - Monohydroxylation LAROPIPRANT [197]
MR005371 Lauric acid 11-hydroxylauric acid Oxidation - Hydrolyzationn Lauric acid [280]
MR003105 Leflunomide . Unclear - Unclear Leflunomide [83]
MR003108 Lesinurad Lesinurad metabolite M3 Oxidation - Hydroxylation Lesinurad [84]
MR003109 Lesinurad Lesinurad metabolite M6 Unclear - Unclear Lesinurad [84]
MR003107 Lesinurad Lesinurad metabolite M3c Oxidation - Oxidation Lesinurad [84]
MR003110 Lesinurad Lesinurad metabolite M3a Oxidation - Hydroxylation Lesinurad [84]
MR003111 Lesinurad Lesinurad metabolite M3b Oxidation - Hydroxylation Lesinurad [84]
MR001555 Lidocaine . Unclear - Unclear Lidocaine [22]
MR012306 LIK-066 LIK-066 M13,14 Oxidation - Oxidation LIK-066 [247]
MR008296 LJN452 LJN452 metabolite M24 Unclear - Unclear LJN452 [248]
MR009967 Lornoxicam 5-hydroxylornoxicam Oxidation - HYDROXYLATION Lornoxicam [367]
MR013896 Losartan E 3179 Unclear - Unclear Losartan [229]
MR013896 Losartan E 3179 Unclear - Unclear Losartan [229]
MR006914 Losartan Carboxaldehyde Losartan carboxylic acid Unclear - Unclear Losartan potassium [36]
MR006916 Losartan potassium Losartan carboxylic acid Oxidation - N-oxidation Losartan potassium [229]
MR006913 Losartan potassium Losartan Carboxaldehyde Oxidation - Oxidationn Losartan potassium [229]
MR006922 beta-hydroxy acid of lovastatin 6'-beta-Hydroxylovastatin Oxidation - Hydrolyzationn Lovastatin [125]
MR001602 Lumiracoxib Lumiracoxib metabolite M21 Oxidation - Methyl-Hydroxylation Lumiracoxib [36]
MR001603 Lumiracoxib Lumiracoxib metabolite M23 Oxidation - Hydroxylation Lumiracoxib [36]
MR003762 LY-450139 LY-2484595 Metabolite M3 Oxidation - Benzylic hydroxylation LY-450139 [230]
MR001609 Lynestrenol Norethindrone Unclear - Unclear Lynestrenol [41]
MR006937 Macitentan Aprocitentan Oxidation - Depropylation Macitentan [62]
MR006942 Macitentan Macitentan metabolite M7 Oxidation - Hydrolyzationn Macitentan [62]
MR006934 Macitentan Macitentan metabolite M4 Oxidation - Oxidationn Macitentan [62]
MR010176 Mavacamten MYK-2210 Unclear - Unclear Mavacamten [368]
MR001630 Mefenamic acid 3-hydroxymethyl Mefenamic Acid Oxidation - Hydroxylation Mefenamic acid [158]
MR002858 5-hydroxymethyl meloxicam 5-Carboxy meloxicam Oxidation - Oxidation Meloxicam [369], [370]
MR002857 Meloxicam 5-hydroxymethyl meloxicam Oxidation - Hydroxylation Meloxicam [369], [370]
MR009971 Mephenytoin Nirvanol Oxidation - Demethylation Mephenytoin [371], [372]
MR001645 17alpha-Ethinylestradiol 2-hydroxyethinylestradiol Oxidation - 2-Hydroxylation Mestranol [190], [191]
MR001646 17alpha-Ethinylestradiol 4-hydroxyethinylestradiol Oxidation - 4-Hydroxylation Mestranol [190], [191]
MR001647 17alpha-Ethinylestradiol 6-hydroxyethinylestradiol Oxidation - 6-Hydroxylation Mestranol [190], [191]
MR001648 17alpha-Ethinylestradiol 7-hydroxyethinylestradiol Oxidation - 7-Hydroxylation Mestranol [190], [191]
MR001649 17alpha-Ethinylestradiol 16alpha-hydroxyethinylestradiol Oxidation - 16-Hydroxylation Mestranol [190], [191]
MR001652 Mestranol 17alpha-Ethinylestradiol Oxidation - O-Demethylation Mestranol [36], [373]
MR001653 Mestranol 17beta-Ethinylestradiol Oxidation - O-Demethylation Mestranol [36]
MR001657 4-formyl-amino-antipyrine (FAA) 4-amino-antipyrine (AA) Oxidation - N-Demethylation Metamizole sodium [374], [375]
MR001655 N-Desmethylaminopyrine 4-amino-antipyrine (AA) Oxidation - N-Demethylation Metamizole sodium [374], [375]
MR009998 Methadone EDDP Oxidation - N-demethylation Methadone [126], [376]
MR013395 Metoclopramide hydrochloride Metoclopramide hydrochloride Metabolite M4 Oxidation - Oxidationn Metoclopramide hydrochloride [377]
MR013401 Metoclopramide hydrochloride Metoclopramide hydrochloride Metabolite M3 Oxidation - N-dealkylation Metoclopramide hydrochloride [377]
MR013406 Metoclopramide hydrochloride Metoclopramide hydrochloride Metabolite M10 Oxidation - Nitration Metoclopramide hydrochloride [377]
MR007634 ML-3000 Licofelone M2 Oxidation - Hydrolyzationn ML-3000 [36]
MR003965 MN-1695 ISG-N-oxide Oxidation - N-oxidation MN-1695 [269]
MR004802 Montelukast sodium 25-OH Montelukast Unclear - Unclear Montelukast sodium [16]
MR004796 Montelukast sodium Montelukast 1, 2-Diol Oxidation - Aliphatic hydroxylation Montelukast sodium [36]
MR004796 Montelukast sodium Montelukast metabolite M6a/b Oxidation - Methyl-hydroxylation Montelukast sodium [36]
MR005404 MRTX849 Unclear Unclear - Unclear MRTX849 [378]
MR003382 R-Naftopidil R-Naftopidil metabolite M1 Unclear - Unclear Naftopidil [198], [379]
MR003383 R-Naftopidil R-Naftopidil metabolite M2 Unclear - Unclear Naftopidil [198], [379]
MR003385 S-Naftopidil R-Naftopidil metabolite M1 Unclear - Unclear Naftopidil [198], [379]
MR003386 S-Naftopidil R-Naftopidil metabolite M2 Unclear - Unclear Naftopidil [198], [379]
MR003387 S-Naftopidil R-Naftopidil metabolite M3 Unclear - Unclear Naftopidil [198], [379]
MR008825 Nalbuphine 3'-hydroxynalbuphine Oxidation - Hydroxylation Nalbuphine [102]
MR008826 Nalbuphine 4'-hydroxynalbuphine Oxidation - Hydroxylation Nalbuphine [102]
MR004871 Naproxen O-Desmethylnaproxen Oxidation - O-demethylation Naproxen [36], [380], [381], [382]
MR004876 Nateglinide Nateglinide metabolite M2/M3 Oxidation - Hydrolyzationn Nateglinide [36], [383]
MR004878 Nateglinide Nateglinide metabolite M1 Oxidation - Hydrolyzationn Nateglinide [36]
MR004883 Nateglinide 2-{[4-(1-hydroxypropan-2-yl)cyclohexyl]formamido}-3-phenylpropanoic acid Oxidation - Aliphatic hydroxylation Nateglinide [36]
MR004884 Nateglinide 2-{[4-(2-hydroxypropan-2-yl)cyclohexyl]formamido}-3-phenylpropanoic acid Oxidation - Aliphatic hydroxylation Nateglinide [36]
MR009257 N-despropyl-rotigotine Neupro Metabolite M2 Unclear - Unclear Neupro [384], [199]
MR009255 Neupro N-despropyl-rotigotine Unclear - Unclear Neupro [384], [199]
MR003269 Nevirapine 12-hydroxynevirapine Oxidation - Hydroxylation Nevirapine [385], [386], [387]
MR001818 Olodaterol hydrochloride O-demethylated olodaterol Oxidation - O-Demethylation Olodaterol hydrochloride [388]
MR001830 Omeprazole 5-hydroxyomeprazole Oxidation - 5-Hydroxylation Omeprazole [36]
MR001857 Ospemifene 4-hydroxylation Ospemifene Unclear - Unclear Ospemifene [104]
MR002868 Paramethadione 5-Ethyl-5-methyl-1,3-oxazolidine-2,4-dione Oxidation - N-Demethylation Paramethadione [176], [389]
MR003485 Valdecoxib Valdecoxib metabolite M1 Oxidation - Methyl-Hydroxylation Parecoxib [390], [36]
MR003491 Valdecoxib Valdecoxib metabolite M9 Oxidation - Hydroxylation Parecoxib [390], [36]
MR001974 Pentobarbital 4-hydroxyphenobarbital Oxidation - Hydroxylation Pentobarbital [391]
MR001986 Perazine N-desmethylperazine Oxidation - N-Demethylation Perazine [392]
MR002005 Perphenazine N-Dealkylated perphenazine Oxidation - N-Dealkylation Perphenazine [393]
MR010398 PF-04937319 PF-04937319 Metabolite M1 Oxidation - N-demethylation PF-04937319 [394]
MR005388 PF-04965842 Abrocitinib M4 metabolite Oxidation - Oxidationn PF-04965842 [395]
MR005393 PF-04965842 Abrocitinib M1 metabolite Oxidation - Oxidationn PF-04965842 [395]
MR005400 PF-04965842 Abrocitinib M3 metabolite Oxidation - Oxidationn PF-04965842 [395]
MR005397 PF-04965842 Abrocitinib M2 metabolite Oxidation - Oxidationn PF-04965842 [395]
MR012168 PF-04965842 PF-04965842 Metabolites M1 Unclear - Unclear PF-04965842 [396]
MR012178 PF-04965842 PF-04965842 Metabolites M2 Unclear - Unclear PF-04965842 [397]
MR002025 Phenprocoumon 4'-hydroxy-R-phenprocoumon Oxidation - 4'-Hydroxylation Phenprocoumon [36]
MR002026 Phenprocoumon 6-hydroxy-R-phenprocoumon Oxidation - 6-Hydroxylation Phenprocoumon [36]
MR002027 Phenprocoumon 8-hydroxy-R-phenprocoumon Oxidation - 8-Hydroxylation Phenprocoumon [36]
MR002028 Phenprocoumon 7-hydroxy-R-phenprocoumon Oxidation - 7-Hydroxylation Phenprocoumon [36]
MR002872 Phenylbutazone Oxyphenbutazone Oxidation - Oxidation Phenylbutazone [398]
MR002873 Phenylbutazone Gamma-hydroxyphenylbutazone Oxidation - Oxidation Phenylbutazone [398]
MR002874 Phenylbutazone Beta-hydroxyphenylbutazone Oxidation - Oxidation Phenylbutazone [399]
MR002875 Phenylbutazone P,gamma-dihydroxyphenylbutazone Oxidation - Oxidation Phenylbutazone [399]
MR002876 Phenylbutazone 4-hydroxyphenylbutazone Oxidation - Oxidation Phenylbutazone [399]
MR002030 Hydroxyphenytoin Phenytoin catechol Oxidation - Oxidation Phenytoin [325]
MR002036 Phenytoin Phenytoin dihydrodiol Oxidation - Dihydroxylation; Oxidation Phenytoin [36]
MR002035 Phenytoin Phenytoin arene-oxide Oxidation - Oxidation Phenytoin [325]
MR002064 Piroxicam 5'-hydroxypiroxicam Oxidation - 5'-Hydroxylation Piroxicam [400], [401]
MR008868 Pitavastatin Pitavastatin metabolite M-13 Oxidation - Oxidation Pitavastatin [34]
MR002068 Pitavastatin M-13 Oxidation - Oxidation Pitavastatin calcium [402]
MR002088 R-95913 R-138727 Unclear - Unclear Prasugrel hydrochloride [36], [403], [404], [405]
MR002149 Primidone Phenylethylmalonamide (PEMA) Unclear - Unclear Primidone [406], [407]
MR002150 Primidone Phenobarbital Unclear - Unclear Primidone [406], [407], [408], [409]
MR002172 Progesterone Desoxycortone Oxidation - Hydroxylation Progesterone [17]
MR002782 Promazine N-Desmethylpromazine Oxidation - N-Demethylation Promazine [87]
MR002187 Propofol 4-hydroxypropofol Oxidation - 4-Hydroxylation Propofol [36]
MR013648 PT2385 PT2385 M10 Oxidation - Hydroxylation PT2385 [249]
MR013646 PT2385 PT2385 M2 Oxidation - Hydroxylation PT2385 [249]
MR002785 2-Oxoquazepam 3-hydroxy-2-oxoquazepam Oxidation - Hydroxylation Quazepam [410]
MR002786 2-Oxoquazepam N-Desalkyl-2-oxoquazepam Unclear - Unclear Quazepam [410]
MR002788 Quazepam 2-Oxoquazepam Hydrolysis - Hydrolysis Quazepam [410]
MR010018 Quinine sulfate Quinine sulfate Metabolite M3 Oxidation - Demethylation Quinine sulfate [411]
MR006424 R-1124 Netupitant N-Oxide Oxidation - Oxidationn R-1124 [412]
MR006425 R-1124 N\demethylated netupitant Oxidation - Demethylation R-1124 [412]
MR006426 R-1124 Monohydroxy netupitant Oxidation - Hydrolyzationn R-1124 [412]
MR008491 Remogliflozin GSK279782 Unclear - Unclear Remogliflozin etabonate [251]
MR006427 RO-111163 Moclobemide M1 Oxidation - C-oxidation RO-111163 [413]
MR006433 RO-111163 Moclobemide M5 Oxidation - N-oxidation RO-111163 [413]
MR006435 RO-111163 Moclobemide M3 Oxidation - Aromatic hydroxylation RO-111163 [413]
MR006436 RO-111163 Moclobemide M9 Oxidation - Oxidationn deamination RO-111163 [413]
MR009576 Rosiglitazone N-Desmethylrosiglitazone Oxidation - N-demethylation Rosiglitazone [36]
MR009582 Rosiglitazone Para-Hydroxyrosiglitazone Oxidation - Hydroxylation Rosiglitazone [36]
MR009586 Rosiglitazone Ortho-Hydroxyrosiglitazone Oxidation - Hydroxylation Rosiglitazone [36]
MR009576 Rosiglitazone N-desmethyl?rosiglitazone Oxidation - N-demethylation Rosiglitazone [414]
MR009582 Rosiglitazone p-hydroxy?rosiglitazone Oxidation - Hydroxylation Rosiglitazone [414]
MR008879 Ruxolitinib Ruxolitinib M16 metabolite Oxidation - 3-hydroxylation Ruxolitinib [415], [416]
MR008881 Ruxolitinib Ruxolitinib M18 metabolite Oxidation - 2-hydroxylation Ruxolitinib [415], [416]
MR008882 Ruxolitinib Ruxolitinib M49 metabolite Unclear - Unclear Ruxolitinib [415], [416]
MR008880 Ruxolitinib M16 metabolite Ruxolitinib M9 metabolite Other reaction - Ketone formation Ruxolitinib [130]
MR002214 Ruxolitinib M16 metabolite Ruxolitinib metabolite M9 Unclear - Unclear Ruxolitinib phosphate [415]
MR002215 Ruxolitinib phosphate Ruxolitinib M16 metabolite Oxidation - 3-Hydroxylation Ruxolitinib phosphate [415]
MR002216 Ruxolitinib phosphate Ruxolitinib M18 metabolite Oxidation - 2-Hydroxylation Ruxolitinib phosphate [415]
MR002217 Ruxolitinib phosphate Ruxolitinib M49 metabolite Unclear - Unclear Ruxolitinib phosphate [415]
MR006453 SC-411 10,11-EDP Unclear - Unclear SC-411 [232]
MR006458 SCH-417690 O-Desmethylvicriviroc Oxidation - O-demethylation SCH-417690 [36]
MR002247 Sertraline hydrochloride Desmethylsertraline Oxidation - N-Demethylation Sertraline hydrochloride [165], [417], [418], [419]
MR013895 Sildenafil N-desmethyl Sildenafil Unclear - Unclear Sildenafil [239], [420], [421]
MR002252 Sildenafil citrate Desmethylsildenafil Oxidation - N-Demethylation Sildenafil citrate [422], [423], [424]
MR002253 Sildenafil citrate N-dealkyl Sildenafil Oxidation - N-Dealkylation Sildenafil citrate [36]
MR002272 Siponimod Siponimod metabolite M1 Oxidation - Hydroxylation Siponimod [35]
MR005264 Sitaxentan Unclear Unclear - Unclear Sitaxentan [218]
MR008425 STX 64 STX 64 metabolite M13 Oxidation - Hydroxylation STX 64 [265]
MR008432 STX 64 STX 64 metabolite M7 Oxidation - Hydroxylation STX 64 [265]
MR008434 STX 64 STX 64 metabolite M18 Unclear - Unclear STX 64 [265]
MR006846 Sulfadiazine Sulfadiazine hydroxylamine Multi-steps Reaction - Hydrolyzationn; sulfadiazine acetylation Sulfadiazine [425]
MR002280 Sulfamethoxazole Sulfamethoxazole N4-hydroxylamine Oxidation - N-Hydroxylation Sulfamethoxazole [36], [109], [426]
MR002305 Suprofen Thiophene-4,5-epoxide Unclear - Unclear Suprofen [36]
MR002306 Suprofen 5-OH-suprofen Oxidation - Oxidation Suprofen [36]
MR002303 Suprofen metabolite M1 Intermediate Suprofen metabolite M1 Oxidation - N-Dealkylation Suprofen [36]
MR002300 Thiophene-4,5-epoxide Suprofen metabolite M2 Unclear - Unclear Suprofen [36]
MR011374 Azilsartan TAK-491 Metabolite M2 Oxidation - O-dealkylation TAK-491 [139]
MR003510 Tamoxifen citrate N-Desmethyltamoxifen Oxidation - N-Dealkylation Tamoxifen citrate [427], [428], [429], [430], [431]
MR002334 Tapentadol N-desmethyl tapentadol Unclear - Unclear Tapentadol [90], [432]
MR011315 Tarafenacin Tarafenacin Metabolite M1 Unclear - Unclear Tarafenacin [250]
MR011316 Tarafenacin Tarafenacin Metabolite M2/M3 Unclear - Unclear Tarafenacin [250]
MR002340 Tasimelteon Tasimelteon metabolite M13 Oxidation - Hydroxylation Tasimelteon [433]
MR002338 Tasimelteon metabolite M13 Tasimelteon metabolite M9 Unclear - Unclear Tasimelteon [433]
MR002376 O-conjugate of temazepam Temazepam metabolite M1 Oxidation - Demethylation Temazepam [434], [435]
MR002378 Temazepam Oxazepam Oxidation - Demethylation Temazepam [436], [434]
MR006162 Tenoxicam 5'-Hydroxytenoxicam Oxidation - 5'-hydroxylation Tenoxicam [437], [438], [439]
MR002399 Hydroxyterbinafine N-Desmethylhydroxyterbinafine Oxidation - N-Demethylation Terbinafine hydrochloride [440], [441]
MR002400 Hydroxyterbinafine Carboxyterbinafine Oxidation - Oxidation Terbinafine hydrochloride [440]
MR002401 N-Desmethylterbinafine N-Desmethylhydroxyterbinafine Oxidation - Hydoxylation Terbinafine hydrochloride [440]
MR002402 N-Desmethylterbinafine N-Desmethylterbinafine dihydrodiol derivative (2) Oxidation - Dihydroxylation Terbinafine hydrochloride [440]
MR002403 N-Desmethylterbinafine N-Desmethylterbinafine dihydrodiol derivative (1) Oxidation - Dihydroxylation Terbinafine hydrochloride [440]
MR002406 Terbinafine dihydrodiol derivative (1) N-Desmethylterbinafine dihydrodiol derivative (1) Oxidation - N-Demethylation Terbinafine hydrochloride [440]
MR002407 Terbinafine dihydrodiol derivative (2) N-Desmethylterbinafine dihydrodiol derivative (2) Oxidation - N-Demethylation Terbinafine hydrochloride [440]
MR002409 Terbinafine hydrochloride N-Desmethylterbinafine Oxidation - N-Demethylation Terbinafine hydrochloride [440]
MR002410 Terbinafine hydrochloride 1-Naphthaldehyde Oxidation - Deamination Terbinafine hydrochloride [440]
MR002408 Terbinafine hydrochloride Hydroxyterbinafine Oxidation - Hydoxylation Terbinafine hydrochloride [440]
MR002411 Terbinafine hydrochloride Terbinafine dihydrodiol derivative (1) Oxidation - Dihydroxylation Terbinafine hydrochloride [440]
MR002412 Terbinafine hydrochloride Terbinafine dihydrodiol derivative (2) Oxidation - Dihydroxylation Terbinafine hydrochloride [440]
MR006174 Thiamylal Thiamylal carboxylic acid Oxidation - Oxidationn Thiamylal [219], [442]
MR006192 Tienilic acid Thiophene-4,5-epoxide Oxidation - Epoxidation Tienilic acid [36]
MR006190 Tienilic acid Ticrynafen S-oxide Oxidation - Oxidationn Tienilic acid [36]
MR006191 Tienilic acid Tienilic acid-s-oxide Oxidation - S-oxidation Tienilic acid [36]
MR006193 Tienilic acid 5-Hydroxy-tienilic Acid Oxidation - Hydrolyzationn Tienilic acid [443], [444]
MR004995 M1 metabolite, timolol Timolol maleate Metabolite M4 Unclear - Unclear Timolol maleate [134]
MR004996 M1 metabolite, timolol Timolol maleate Metabolite M3 Unclear - Unclear Timolol maleate [134]
MR004997 Timolol maleate Timolol maleate Metabolite M2 Unclear - Unclear Timolol maleate [134]
MR004994 Timolol maleate M1 metabolite, timolol Oxidation - Hydrolyzationn Timolol maleate [134], [445]
MR006775 Tolbutamide 4-Hydroxy tolbutamide Oxidation - Hydrolyzationn Tolbutamide [36]
MR006780 Tolterodine tartrate N-Dealkylated tolterodine Oxidation - N-dealkylation Tolterodine tartrate [36]
MR006800 Torasemide Torasemide metabolite M1 (hydroxytorsemide) Oxidation - Hydrolyzationn Torasemide [446]
MR006802 Torasemide Torasemide metabolite M4 Oxidation - Hydrolyzationn Torasemide [446]
MR006803 Torasemide Torasemide metabolite M2 Reduction - Reduction Torasemide [446]
MR006804 Torasemide Torasemide metabolite M3 Oxidation - Hydrolyzationn Torasemide [446]
MR012214 TR-14035 TR-14081 Oxidation - O-desmethylation TR-14035 [276]
MR006194 Tranilast 4-demethyltranilast Oxidation - 4-demethylation Tranilast [209], [447]
MR006198 Tranilast Tranilast metabolite N-4 Oxidation - Demethylation Tranilast [447]
MR009636 Tretinoin 18-OH-RA Oxidation - Hydroxylation Tretinoin [448], [449], [81]
MR009629 Tretinoin 5,6-epoxy-RA Oxidation - Ring epoxidation Tretinoin [449], [449], [448]
MR009634 Tretinoin 9-cis RA Other reaction - Isomerization Tretinoin [81], [449]
MR002452 Trifarotene . Unclear - Unclear Trifarotene [450]
MR002911 Trimethadione Dimethadione Oxidation - N-Demethylation Trimethadione [451], [180]
MR006150 TRV-130 Oxy-oliceridine Oxidation - Oxidationn TRV-130 [263]
MR006152 TRV-130 TRV0109662 Oxidation - N-dealkylation TRV-130 [263]
MR006991 VA-10872 3'-Hydroxyhexobarbital Oxidation - 3'-hydroxylation VA-10872 [36]
MR003302 Valdecoxib Valdecoxib metabolite M1 Oxidation - Methyl-Hydroxylation Valdecoxib [390], [36]
MR003300 Valdecoxib metabolite M9 Valdecoxib metabolite M9-G Unclear - Unclear Valdecoxib [390]
MR002487 2-N-Propyl-4-oxopentanoic acid 2-Propylsuccinic acid Oxidation - 5-Hydroxylation Valproic acid [36]
MR002492 Valproic acid 4-hydroxyvalproic acid Oxidation - 4-Hydroxylation Valproic acid [36]
MR002494 Valproic acid 5-hydroxyvalproic acid Oxidation - 5-Hydroxylation Valproic acid [36]
MR002493 Valproic acid 4-ene-Valproic acid Oxidation - 3-Hydroxylation Valproic acid [36]
MR002501 Valsartan Valeryl-4-hydroxyvalsartan Oxidation - 4-Hydroxylation Valsartan [452], [453], [454]
MR008277 VATALANIB VATALANIB metabolite M1 Unclear - Unclear VATALANIB [250]
MR005638 Desvenlafaxine N,O-Didesmethylvenlafaxine Oxidation - N-demethylation Venlafaxine hydrochloride [114], [455], [456]
MR005642 Venlafaxine hydrochloride N-Desmethylvenlafaxine Oxidation - N-demethylation Venlafaxine hydrochloride [114], [455], [456]
MR010529 Verapamil D-702 Unclear - Unclear Verapamil [36]
MR010531 Verapamil N19 (D-703) Unclear - Unclear Verapamil [36]
MR005650 Verapamil hydrochloride O-Desmethylverapamil (D-702) Oxidation - O-demethylation Verapamil hydrochloride [36]
MR005652 Verapamil hydrochloride O-Desmethylverapamil (D-703) Oxidation - O-demethylation Verapamil hydrochloride [36]
MR005655 Vismodegib Vismodegib metabolite M3 Oxidation - Hydrolyzationn Vismodegib [457], [458], [459]
MR013078 TAK-438 N-sulfate Vonoprazan M--Sul Oxidation - Hydroxylation Vonoprazan [460], [201]
MR013245 Voriconazole Voriconazole N-Oxide Metabolite Oxidation - Oxidationn Voriconazole [461], [462]
MR005673 Vortioxetine hydrobromide Vortioxetine Metabolite 2 Oxidation - Hydrolyzationn Vortioxetine hydrobromide [115], [463]
MR005668 Vortioxetine hydrobromide Vortioxetine Metabolite 1 Oxidation - Hydrolyzationn Vortioxetine hydrobromide [115], [463]
MR005671 Vortioxetine hydrobromide LU-AA39835 Oxidation - Hydrolyzationn Vortioxetine hydrobromide [115], [463]
MR005675 Voxelotor Unclear Oxidation - Oxidationn Voxelotor [464]
MR013265 Warfarin sodium S-6-Hydroxywarfarin Oxidation - 6-hydroxylation Warfarin sodium [216], [87]
MR013268 Warfarin sodium S-7-Hydroxywarfarin Oxidation - 7-hydroxylation Warfarin sodium [216], [87]
MR006071 Z-4828 L-ifosfamide Oxidation - Aliphatic hydroxylation Z-4828 [255]
MR013282 Zafirlukast Zafirlukast metabolite M5 Unclear - Unclear Zafirlukast [36], [465]
MR013286 Zafirlukast Zafirlukast metabolite M6 Unclear - Unclear Zafirlukast [36], [465]
MR009646 Zaltoprofen 10-OH-zaltoprofen (M3) Oxidation - Hydroxylation Zaltoprofen [36]
MR005676 Zidovudine 3'-Aminothymidine Reduction - Reduction Zidovudine [22], [466]
MR013298 Dehydroxyzyleuton OH-dehydroxyzileuton Oxidation - Hydrolyzationn Zileuton [36], [331]
MR013299 Zileuton Hydroxyzileuton Oxidation - Hydrolyzationn Zileuton [36], [331]
MR005696 Zolpidem tartrate Methoxyzolpidem derivative (M3) Oxidation - Methyl-hydroxylation Zolpidem tartrate [36], [467]
MR005702 Zolpidem tartrate Methoxyzolpidem Oxidation - Aliphatic hydroxylation Zolpidem tartrate [36], [467]
MR009649 Zopiclone Zopiclone N-oxide Oxidation - N-oxidation Zopiclone [36], [468]
MR009651 Zopiclone N-desmethylzopiclone Oxidation - N-demethylation Zopiclone [36], [468]
⏷ Show the Full List of 428 MR(s)
Tissue/Disease-Specific Protein Abundances of This DME
      Tissue-specific Protein Abundances in Healthy Individuals Click to Show/Hide
Download the Tissue-Specific Variation(s) Profile
      ICD Disease Classification 01 Infectious/parasitic disease Click to Show/Hide
                  ICD-11: 1C1H     Necrotising ulcerative gingivitis Click to Show/Hide
The Studied Tissue     Gingival tissue
The Specified Disease     Bacterial infection of gingival [ICD-11:1C1H]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.43E-24; Fold-change: -6.29E-01; Z-score: -1.88E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 1E30     Influenza Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Influenza [ICD-11:1E30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.74E-01; Fold-change: 2.46E-01; Z-score: 9.22E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 1E51     Chronic viral hepatitis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Chronic hepatitis C [ICD-11:1E51.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.98E-01; Fold-change: -3.47E-03; Z-score: -1.39E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 1G41     Sepsis with septic shock Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Sepsis with septic shock [ICD-11:1G41]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.64E-02; Fold-change: 1.15E-01; Z-score: 3.95E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA40     Respiratory syncytial virus infection Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Pediatric respiratory syncytial virus infection [ICD-11:CA40.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.84E-01; Fold-change: -4.96E-02; Z-score: -2.85E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA42     Rhinovirus infection Click to Show/Hide
The Studied Tissue     Nasal epithelium tissue
The Specified Disease     Rhinovirus infection [ICD-11:CA42.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.34E-01; Fold-change: 4.64E-04; Z-score: 3.34E-03
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: KA60     Neonatal sepsis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Neonatal sepsis [ICD-11:KA60]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.69E-02; Fold-change: 1.06E-01; Z-score: 3.95E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 02 Neoplasm Click to Show/Hide
                  ICD-11: 2A00     Brain cancer Click to Show/Hide
The Studied Tissue     Nervous tissue
The Specified Disease     Glioblastopma [ICD-11:2A00.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.53E-12; Fold-change: -3.19E-01; Z-score: -7.75E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Brain stem tissue
The Specified Disease     Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.93E-01; Fold-change: -7.33E-03; Z-score: -1.14E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     White matter tissue
The Specified Disease     Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.46E-03; Fold-change: -4.23E-01; Z-score: -2.75E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Brain stem tissue
The Specified Disease     Neuroectodermal tumour [ICD-11:2A00.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.82E-05; Fold-change: -1.32E+00; Z-score: -2.53E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A20     Myeloproliferative neoplasm Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Myelofibrosis [ICD-11:2A20.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.76E-04; Fold-change: 1.89E-01; Z-score: 8.57E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Whole blood
The Specified Disease     Polycythemia vera [ICD-11:2A20.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.78E-03; Fold-change: 8.00E-02; Z-score: 4.77E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A36     Myelodysplastic syndrome Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Myelodysplastic syndrome [ICD-11:2A36-2A3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.96E-01; Fold-change: -9.61E-03; Z-score: -2.89E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 6.46E-01; Fold-change: -5.23E-02; Z-score: -4.98E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A81     Diffuse large B-cell lymphoma Click to Show/Hide
The Studied Tissue     Tonsil tissue
The Specified Disease     Diffuse large B-cell lymphoma [ICD-11:2A81]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.67E-01; Fold-change: -1.78E-02; Z-score: -1.15E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2A83     Plasma cell neoplasm Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.70E-01; Fold-change: 1.32E-01; Z-score: 9.13E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Bone marrow
The Specified Disease     Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.83E-04; Fold-change: -7.08E-01; Z-score: -2.91E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B33     Leukaemia Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Acute myelocytic leukaemia [ICD-11:2B33.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.63E-01; Fold-change: -9.82E-03; Z-score: -4.80E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B6E     Oral cancer Click to Show/Hide
The Studied Tissue     Oral tissue
The Specified Disease     Oral cancer [ICD-11:2B6E]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.09E-05; Fold-change: -8.12E-01; Z-score: -1.13E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.06E-45; Fold-change: -1.58E+00; Z-score: -2.78E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B70     Esophageal cancer Click to Show/Hide
The Studied Tissue     Esophagus
The Specified Disease     Esophagal cancer [ICD-11:2B70]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.62E-01; Fold-change: -5.78E-01; Z-score: -4.78E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: 2B72     Stomach cancer Click to Show/Hide
The Studied Tissue     Gastric tissue
The Specified Disease     Gastric cancer [ICD-11:2B72]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.80E-01; Fold-change: -2.27E+00; Z-score: -1.68E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 8.73E-08; Fold-change: -1.76E+00; Z-score: -2.21E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B90     Colon cancer Click to Show/Hide
The Studied Tissue     Colon tissue
The Specified Disease     Colon cancer [ICD-11:2B90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.35E-09; Fold-change: -5.03E-01; Z-score: -6.35E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.35E-04; Fold-change: -2.35E-01; Z-score: -2.71E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2B92     Rectal cancer Click to Show/Hide
The Studied Tissue     Rectal colon tissue
The Specified Disease     Rectal cancer [ICD-11:2B92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.04E-01; Fold-change: -5.14E-02; Z-score: -1.57E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.18E-01; Fold-change: 2.37E-01; Z-score: 6.08E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C10     Pancreatic cancer Click to Show/Hide
The Studied Tissue     Pancreas
The Specified Disease     Pancreatic cancer [ICD-11:2C10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.36E-02; Fold-change: 5.20E-01; Z-score: 5.54E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.89E-02; Fold-change: 8.19E-01; Z-score: 5.11E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C12     Liver cancer Click to Show/Hide
The Studied Tissue     Liver tissue
The Specified Disease     Liver cancer [ICD-11:2C12.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.95E-34; Fold-change: -1.91E+00; Z-score: -2.96E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.08E-71; Fold-change: -1.92E+00; Z-score: -4.42E+00
The Expression Level of Disease Section Compare with the Other Disease Section     p-value: 3.07E-76; Fold-change: -1.97E+00; Z-score: -6.29E+01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
Download DME expression data in the tissue of the other disease section
                  ICD-11: 2C25     Lung cancer Click to Show/Hide
The Studied Tissue     Lung tissue
The Specified Disease     Lung cancer [ICD-11:2C25]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.08E-03; Fold-change: 1.76E-02; Z-score: 7.09E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 7.39E-06; Fold-change: 9.49E-03; Z-score: 4.90E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C30     Skin cancer Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Melanoma [ICD-11:2C30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.22E-02; Fold-change: -4.36E-02; Z-score: -5.84E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Skin
The Specified Disease     Skin cancer [ICD-11:2C30-2C3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.91E-03; Fold-change: -1.59E-01; Z-score: -3.84E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.27E-01; Fold-change: -1.55E-01; Z-score: -3.08E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C6Z     Breast cancer Click to Show/Hide
The Studied Tissue     Breast tissue
The Specified Disease     Breast cancer [ICD-11:2C60-2C6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.07E-11; Fold-change: -1.16E-01; Z-score: -2.53E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 6.69E-02; Fold-change: -1.28E-02; Z-score: -3.31E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C73     Ovarian cancer Click to Show/Hide
The Studied Tissue     Ovarian tissue
The Specified Disease     Ovarian cancer [ICD-11:2C73]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.69E-01; Fold-change: 6.97E-02; Z-score: 1.48E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.97E-08; Fold-change: 9.08E-02; Z-score: 5.54E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C77     Cervical cancer Click to Show/Hide
The Studied Tissue     Cervical tissue
The Specified Disease     Cervical cancer [ICD-11:2C77]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.97E-02; Fold-change: -4.39E-01; Z-score: -8.20E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C78     Uterine cancer Click to Show/Hide
The Studied Tissue     Endometrium tissue
The Specified Disease     Uterine cancer [ICD-11:2C78]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.46E-05; Fold-change: -2.53E-01; Z-score: -2.36E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 1.32E-01; Fold-change: 6.61E-02; Z-score: 3.21E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C82     Prostate cancer Click to Show/Hide
The Studied Tissue     Prostate
The Specified Disease     Prostate cancer [ICD-11:2C82]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.97E-04; Fold-change: -1.04E+00; Z-score: -1.67E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C90     Renal cancer Click to Show/Hide
The Studied Tissue     Kidney
The Specified Disease     Renal cancer [ICD-11:2C90-2C91]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.62E-02; Fold-change: -4.23E-01; Z-score: -1.25E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 6.28E-20; Fold-change: -8.75E-01; Z-score: -2.07E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C92     Ureter cancer Click to Show/Hide
The Studied Tissue     Urothelium
The Specified Disease     Ureter cancer [ICD-11:2C92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.40E-01; Fold-change: -1.32E-03; Z-score: -7.76E-03
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2C94     Bladder cancer Click to Show/Hide
The Studied Tissue     Bladder tissue
The Specified Disease     Bladder cancer [ICD-11:2C94]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.33E-04; Fold-change: 9.95E-01; Z-score: 3.23E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D02     Retinal cancer Click to Show/Hide
The Studied Tissue     Uvea
The Specified Disease     Retinoblastoma [ICD-11:2D02.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.01E-04; Fold-change: -2.94E-01; Z-score: -1.95E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D10     Thyroid cancer Click to Show/Hide
The Studied Tissue     Thyroid
The Specified Disease     Thyroid cancer [ICD-11:2D10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.84E-06; Fold-change: 1.24E-01; Z-score: 6.31E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 4.18E-01; Fold-change: -3.93E-02; Z-score: -2.10E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D11     Adrenal cancer Click to Show/Hide
The Studied Tissue     Adrenal cortex
The Specified Disease     Adrenocortical carcinoma [ICD-11:2D11.Z]
The Expression Level of Disease Section Compare with the Other Disease Section     p-value: 9.72E-03; Fold-change: -1.02E-01; Z-score: -6.69E-01
DME expression in the diseased tissue of patients
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of the other disease section
                  ICD-11: 2D12     Endocrine gland neoplasm Click to Show/Hide
The Studied Tissue     Pituitary tissue
The Specified Disease     Pituitary cancer [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.63E-01; Fold-change: 1.21E-01; Z-score: 3.60E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Pituitary tissue
The Specified Disease     Pituitary gonadotrope tumour [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.04E-02; Fold-change: 3.10E-01; Z-score: 1.42E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 2D42     Head and neck cancer Click to Show/Hide
The Studied Tissue     Head and neck tissue
The Specified Disease     Head and neck cancer [ICD-11:2D42]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.60E-34; Fold-change: -1.33E+00; Z-score: -2.50E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 03 Blood/blood-forming organ disease Click to Show/Hide
                  ICD-11: 3A51     Sickle cell disorder Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Sickle cell disease [ICD-11:3A51.0-3A51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.69E-02; Fold-change: 1.66E-01; Z-score: 8.10E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 3A70     Aplastic anaemia Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Shwachman-Diamond syndrome [ICD-11:3A70.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.21E-01; Fold-change: 5.16E-01; Z-score: 1.33E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 3B63     Thrombocytosis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Thrombocythemia [ICD-11:3B63]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.18E-02; Fold-change: 7.53E-02; Z-score: 3.45E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 3B64     Thrombocytopenia Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Thrombocytopenia [ICD-11:3B64]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.69E-01; Fold-change: 4.32E-04; Z-score: 3.45E-03
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 04 Immune system disease Click to Show/Hide
                  ICD-11: 4A00     Immunodeficiency Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Immunodeficiency [ICD-11:4A00-4A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.43E-01; Fold-change: -2.09E-02; Z-score: -1.29E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A40     Lupus erythematosus Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Lupus erythematosus [ICD-11:4A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.68E-01; Fold-change: -3.49E-02; Z-score: -8.01E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A42     Systemic sclerosis Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Scleroderma [ICD-11:4A42.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.23E-04; Fold-change: -3.65E-01; Z-score: -2.31E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A43     Systemic autoimmune disease Click to Show/Hide
The Studied Tissue     Salivary gland tissue
The Specified Disease     Sjogren's syndrome [ICD-11:4A43.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.22E-01; Fold-change: 9.30E-03; Z-score: 3.20E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 4.14E-02; Fold-change: -4.16E-01; Z-score: -2.26E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4A62     Behcet disease Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Behcet's disease [ICD-11:4A62]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.44E-01; Fold-change: 6.98E-02; Z-score: 3.83E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 4B04     Monocyte count disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Autosomal dominant monocytopenia [ICD-11:4B04]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.22E-01; Fold-change: -4.70E-02; Z-score: -3.26E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 05 Endocrine/nutritional/metabolic disease Click to Show/Hide
                  ICD-11: 5A11     Type 2 diabetes mellitus Click to Show/Hide
The Studied Tissue     Omental adipose tissue
The Specified Disease     Obesity related type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.69E-01; Fold-change: 4.67E-02; Z-score: 5.90E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Liver tissue
The Specified Disease     Type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.93E-01; Fold-change: -5.40E-02; Z-score: -2.92E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5A80     Ovarian dysfunction Click to Show/Hide
The Studied Tissue     Vastus lateralis muscle
The Specified Disease     Polycystic ovary syndrome [ICD-11:5A80.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.74E-01; Fold-change: 5.62E-02; Z-score: 1.87E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5C51     Inborn carbohydrate metabolism disorder Click to Show/Hide
The Studied Tissue     Biceps muscle
The Specified Disease     Pompe disease [ICD-11:5C51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.55E-02; Fold-change: -8.95E-02; Z-score: -5.46E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5C56     Lysosomal disease Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Batten disease [ICD-11:5C56.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.95E-01; Fold-change: -2.28E-02; Z-score: -2.92E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 5C80     Hyperlipoproteinaemia Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.22E-01; Fold-change: 2.66E-02; Z-score: 2.11E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Whole blood
The Specified Disease     Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.63E-03; Fold-change: -1.18E-01; Z-score: -3.80E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 06 Mental/behavioural/neurodevelopmental disorder Click to Show/Hide
                  ICD-11: 6A02     Autism spectrum disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Autism [ICD-11:6A02]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.66E-01; Fold-change: -1.19E-02; Z-score: -7.61E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 6A20     Schizophrenia Click to Show/Hide
The Studied Tissue     Prefrontal cortex
The Specified Disease     Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.99E-01; Fold-change: -6.93E-03; Z-score: -1.36E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Superior temporal cortex
The Specified Disease     Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.21E-01; Fold-change: 7.31E-03; Z-score: 6.10E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 6A60     Bipolar disorder Click to Show/Hide
The Studied Tissue     Prefrontal cortex
The Specified Disease     Bipolar disorder [ICD-11:6A60-6A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.05E-01; Fold-change: -3.98E-02; Z-score: -2.83E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 6A70     Depressive disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.67E-01; Fold-change: 2.59E-02; Z-score: 1.20E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Hippocampus
The Specified Disease     Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.83E-01; Fold-change: 2.32E-03; Z-score: 1.53E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 08 Nervous system disease Click to Show/Hide
                  ICD-11: 8A00     Parkinsonism Click to Show/Hide
The Studied Tissue     Substantia nigra tissue
The Specified Disease     Parkinson's disease [ICD-11:8A00.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.35E-01; Fold-change: 2.78E-02; Z-score: 2.09E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A01     Choreiform disorder Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Huntington's disease [ICD-11:8A01.10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.24E-01; Fold-change: -2.99E-02; Z-score: -3.40E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A20     Alzheimer disease Click to Show/Hide
The Studied Tissue     Entorhinal cortex
The Specified Disease     Alzheimer's disease [ICD-11:8A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.90E-01; Fold-change: -9.81E-03; Z-score: -5.96E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A2Y     Neurocognitive impairment Click to Show/Hide
The Studied Tissue     White matter tissue
The Specified Disease     HIV-associated neurocognitive impairment [ICD-11:8A2Y-8A2Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.29E-02; Fold-change: -2.43E-02; Z-score: -8.06E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8A40     Multiple sclerosis Click to Show/Hide
The Studied Tissue     Plasmacytoid dendritic cells
The Specified Disease     Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.09E-01; Fold-change: -9.26E-02; Z-score: -3.68E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Spinal cord
The Specified Disease     Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 3.71E-01; Fold-change: -1.39E-01; Z-score: -8.19E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: 8A60     Epilepsy Click to Show/Hide
The Studied Tissue     Peritumoral cortex tissue
The Specified Disease     Epilepsy [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Other Disease Section     p-value: 2.08E-01; Fold-change: 1.24E-01; Z-score: 6.43E-01
DME expression in the diseased tissue of patients
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of the other disease section
The Studied Tissue     Whole blood
The Specified Disease     Seizure [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 8.61E-01; Fold-change: 1.32E-01; Z-score: 7.15E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8B01     Subarachnoid haemorrhage Click to Show/Hide
The Studied Tissue     Intracranial artery
The Specified Disease     Intracranial aneurysm [ICD-11:8B01.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.35E-01; Fold-change: 7.01E-02; Z-score: 4.26E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8B11     Cerebral ischaemic stroke Click to Show/Hide
The Studied Tissue     Whole blood
The Specified Disease     Cardioembolic stroke [ICD-11:8B11.20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.76E-04; Fold-change: 1.36E-01; Z-score: 1.00E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Peripheral blood
The Specified Disease     Ischemic stroke [ICD-11:8B11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.86E-01; Fold-change: 6.16E-02; Z-score: 2.91E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8B60     Motor neuron disease Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.31E-01; Fold-change: 2.00E-02; Z-score: 1.82E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Cervical spinal cord
The Specified Disease     Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.00E-01; Fold-change: 4.21E-02; Z-score: 3.26E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8C70     Muscular dystrophy Click to Show/Hide
The Studied Tissue     Muscle tissue
The Specified Disease     Myopathy [ICD-11:8C70.6]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.14E-01; Fold-change: -1.32E-01; Z-score: -7.08E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: 8C75     Distal myopathy Click to Show/Hide
The Studied Tissue     Muscle tissue
The Specified Disease     Tibial muscular dystrophy [ICD-11:8C75]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.55E-01; Fold-change: -9.41E-02; Z-score: -5.58E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 09 Visual system disease Click to Show/Hide
                  ICD-11: 9A96     Anterior uveitis Click to Show/Hide
The Studied Tissue     Peripheral monocyte
The Specified Disease     Autoimmune uveitis [ICD-11:9A96]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.82E-01; Fold-change: -9.64E-02; Z-score: -5.91E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 11 Circulatory system disease Click to Show/Hide
                  ICD-11: BA41     Myocardial infarction Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Myocardial infarction [ICD-11:BA41-BA50]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.91E-02; Fold-change: 2.91E-01; Z-score: 5.07E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: BA80     Coronary artery disease Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Coronary artery disease [ICD-11:BA80-BA8Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.20E-01; Fold-change: -2.18E-02; Z-score: -2.26E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: BB70     Aortic valve stenosis Click to Show/Hide
The Studied Tissue     Calcified aortic valve
The Specified Disease     Aortic stenosis [ICD-11:BB70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.97E-01; Fold-change: -3.93E-02; Z-score: -4.88E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 12 Respiratory system disease Click to Show/Hide
                  ICD-11: 7A40     Central sleep apnoea Click to Show/Hide
The Studied Tissue     Hyperplastic tonsil
The Specified Disease     Apnea [ICD-11:7A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.42E-01; Fold-change: -1.95E-01; Z-score: -4.99E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA08     Vasomotor or allergic rhinitis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Olive pollen allergy [ICD-11:CA08.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.96E-03; Fold-change: 2.40E-01; Z-score: 6.04E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA0A     Chronic rhinosinusitis Click to Show/Hide
The Studied Tissue     Sinus mucosa tissue
The Specified Disease     Chronic rhinosinusitis [ICD-11:CA0A]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 6.84E-01; Fold-change: 1.84E-02; Z-score: 1.37E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA22     Chronic obstructive pulmonary disease Click to Show/Hide
The Studied Tissue     Lung tissue
The Specified Disease     Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.33E-02; Fold-change: 5.59E-02; Z-score: 2.99E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Small airway epithelium
The Specified Disease     Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.65E-03; Fold-change: -7.28E-02; Z-score: -1.24E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CA23     Asthma Click to Show/Hide
The Studied Tissue     Nasal and bronchial airway
The Specified Disease     Asthma [ICD-11:CA23]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.25E-03; Fold-change: -4.98E-01; Z-score: -6.49E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: CB03     Idiopathic interstitial pneumonitis Click to Show/Hide
The Studied Tissue     Lung tissue
The Specified Disease     Idiopathic pulmonary fibrosis [ICD-11:CB03.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.00E-01; Fold-change: 3.06E-02; Z-score: 1.84E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 13 Digestive system disease Click to Show/Hide
                  ICD-11: DA0C     Periodontal disease Click to Show/Hide
The Studied Tissue     Gingival tissue
The Specified Disease     Periodontal disease [ICD-11:DA0C]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 6.62E-17; Fold-change: -5.67E-01; Z-score: -1.49E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: DA42     Gastritis Click to Show/Hide
The Studied Tissue     Gastric antrum tissue
The Specified Disease     Eosinophilic gastritis [ICD-11:DA42.2]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.78E-02; Fold-change: -7.28E-01; Z-score: -1.31E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
                  ICD-11: DB92     Non-alcoholic fatty liver disease Click to Show/Hide
The Studied Tissue     Liver tissue
The Specified Disease     Non-alcoholic fatty liver disease [ICD-11:DB92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.19E-01; Fold-change: 9.45E-02; Z-score: 1.75E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: DB99     Hepatic failure Click to Show/Hide
The Studied Tissue     Liver tissue
The Specified Disease     Liver failure [ICD-11:DB99.7-DB99.8]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.26E-03; Fold-change: -3.74E+00; Z-score: -9.96E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: DD71     Ulcerative colitis Click to Show/Hide
The Studied Tissue     Colon mucosal tissue
The Specified Disease     Ulcerative colitis [ICD-11:DD71]
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 3.00E-01; Fold-change: 1.20E-01; Z-score: 2.52E-01
DME expression in the diseased tissue of patients
DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of the other disease section
                  ICD-11: DD91     Irritable bowel syndrome Click to Show/Hide
The Studied Tissue     Rectal colon tissue
The Specified Disease     Irritable bowel syndrome [ICD-11:DD91.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.48E-04; Fold-change: 3.43E-01; Z-score: 6.77E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 14 Skin disease Click to Show/Hide
                  ICD-11: EA80     Atopic eczema Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Atopic dermatitis [ICD-11:EA80]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.06E-06; Fold-change: -4.93E-01; Z-score: -1.66E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: EA90     Psoriasis Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Psoriasis [ICD-11:EA90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.22E-05; Fold-change: 1.49E-01; Z-score: 5.34E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue     p-value: 2.37E-01; Fold-change: 8.23E-02; Z-score: 1.62E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue adjacent to the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
Download DME expression data in the tissue of healthy individual
                  ICD-11: ED63     Acquired hypomelanotic disorder Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Vitiligo [ICD-11:ED63.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.43E-01; Fold-change: -3.38E-01; Z-score: -8.82E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: ED70     Alopecia or hair loss Click to Show/Hide
The Studied Tissue     Skin from scalp
The Specified Disease     Alopecia [ICD-11:ED70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.96E-01; Fold-change: -1.10E-01; Z-score: -1.61E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: EK0Z     Contact dermatitis Click to Show/Hide
The Studied Tissue     Skin
The Specified Disease     Sensitive skin [ICD-11:EK0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.42E-02; Fold-change: 1.53E-01; Z-score: 1.10E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 15 Musculoskeletal system/connective tissue disease Click to Show/Hide
                  ICD-11: FA00     Osteoarthritis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Arthropathy [ICD-11:FA00-FA5Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.33E-01; Fold-change: 2.06E-02; Z-score: 1.51E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Synovial tissue
The Specified Disease     Osteoarthritis [ICD-11:FA00-FA0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.34E-03; Fold-change: -2.37E-01; Z-score: -1.13E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FA20     Rheumatoid arthritis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Childhood onset rheumatic disease [ICD-11:FA20.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 7.49E-01; Fold-change: -3.67E-02; Z-score: -1.81E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
The Studied Tissue     Synovial tissue
The Specified Disease     Rheumatoid arthritis [ICD-11:FA20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.28E-02; Fold-change: -1.99E-01; Z-score: -6.09E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FA24     Juvenile idiopathic arthritis Click to Show/Hide
The Studied Tissue     Peripheral blood
The Specified Disease     Juvenile idiopathic arthritis [ICD-11:FA24]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.24E-01; Fold-change: 6.31E-02; Z-score: 1.90E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FA92     Inflammatory spondyloarthritis Click to Show/Hide
The Studied Tissue     Pheripheral blood
The Specified Disease     Ankylosing spondylitis [ICD-11:FA92.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.93E-01; Fold-change: 1.60E-02; Z-score: 8.67E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: FB83     Low bone mass disorder Click to Show/Hide
The Studied Tissue     Bone marrow
The Specified Disease     Osteoporosis [ICD-11:FB83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 4.63E-01; Fold-change: -2.60E-02; Z-score: -2.43E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 16 Genitourinary system disease Click to Show/Hide
                  ICD-11: GA10     Endometriosis Click to Show/Hide
The Studied Tissue     Endometrium tissue
The Specified Disease     Endometriosis [ICD-11:GA10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 9.10E-03; Fold-change: 4.31E-01; Z-score: 9.29E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: GC00     Cystitis Click to Show/Hide
The Studied Tissue     Bladder tissue
The Specified Disease     Interstitial cystitis [ICD-11:GC00.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 1.20E-02; Fold-change: 1.20E-01; Z-score: 1.59E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 19 Condition originating in perinatal period Click to Show/Hide
                  ICD-11: KA21     Short gestation disorder Click to Show/Hide
The Studied Tissue     Myometrium
The Specified Disease     Preterm birth [ICD-11:KA21.4Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 2.10E-01; Fold-change: -2.96E-03; Z-score: -1.75E-02
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
      ICD Disease Classification 20 Developmental anomaly Click to Show/Hide
                  ICD-11: LD2C     Overgrowth syndrome Click to Show/Hide
The Studied Tissue     Adipose tissue
The Specified Disease     Simpson golabi behmel syndrome [ICD-11:LD2C]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 5.75E-01; Fold-change: 8.65E-02; Z-score: 8.35E-01
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
                  ICD-11: LD2D     Phakomatoses/hamartoneoplastic syndrome Click to Show/Hide
The Studied Tissue     Perituberal tissue
The Specified Disease     Tuberous sclerosis complex [ICD-11:LD2D.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue     p-value: 3.56E-01; Fold-change: 1.51E-01; Z-score: 1.30E+00
DME expression in the diseased tissue of patients
DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances Click to View the Clearer Original Diagram
Download DME expression barchart for all samples
Download DME expression data of patients in the disease section of the tissue
Download DME expression data in the tissue of healthy individual
References
1 Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
2 Product Monograph of Wellbutrin SR(Bupropion Hydrochloride).
3 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
4 Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans
5 Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001 Apr;41(4):455-8.
6 Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation
7 Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
8 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
9 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
10 Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
11 In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull. 2011;34(5):734-9.
12 CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
13 Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
14 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
15 Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects
16 In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
17 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
18 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
19 Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method
20 DrugBank(Pharmacology-Metabolism):Rosiglitazone
21 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
22 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
23 Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
24 Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.
25 Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol Drug Metab Dispos. 2021 Oct;49(10):882-891. doi: 10.1124/dmd.120.000350.
26 Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
27 Product monograph: CARDURA (Doxazosin mesylate).
28 The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
29 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
30 Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol. 2003 Jun;9(6):1342-6.
31 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
32 CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans
33 Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans
34 Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans
35 Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
36 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
37 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
38 Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
39 Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid. 2013;8:27-35.
40 In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition Xenobiotica. 2008 May;38(5):496-510. doi: 10.1080/00498250801956350.
41 Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
42 Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013 Nov 26;4:147.
43 In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
44 In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
45 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
46 Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
47 Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
48 Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
49 Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther. 1996 Dec;279(3):1327-34.
50 Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab Dispos. 2003 Nov;31(11):1369-77.
51 DailyMed : Alitretinoin
52 Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica. 2013 Dec;43(12):1037-42.
53 The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86.
54 Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
55 Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
56 Phenytoin-diazepam interaction. Ann Pharmacother. 2003 May;37(5):659-63.
57 Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
58 FDA Approved Drug Products: Perforomist? inhalation solution
59 In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
60 Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
61 In?vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
62 Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan
63 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
64 Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
65 Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
66 Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos. 2001 May;29(5):701-11.
67 Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75.
68 Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002 Jun;30(6):631-5.
69 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
70 Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
71 Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
72 Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013 Aug;14(7):421-9.
73 FDA LABEL:Avanafil
74 Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies
75 Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
76 Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
77 FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
78 Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
79 Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70.
80 Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett. 2012 Jun 1;6(2):94-101.
81 Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids
82 Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
83 Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004 Jan;36(1):82-4.
84 Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549.
85 Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol. 1997 Apr;37(4):267-78.
86 Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010 Sep;8(3):254-67.
87 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635.
88 Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999 Dec;48(6):829-38.
89 DrugBank(Pharmacology-Metabolism):Simvastatin
90 Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
91 The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
92 Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos. 1995 Oct;23(10):1163-74.
93 The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
94 Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes Med Sci Monit. 2013 May 27;19:394-408. doi: 10.12659/MSM.883922.
95 Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
96 FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
97 Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
98 Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
99 Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9.
100 Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
101 Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 Jan;77(1):1-16.
102 A dual system platform for drug metabolism: Nalbuphine as a model compound
103 Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
104 Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
105 CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5. doi: 10.1007/s002280050703.
106 Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
107 Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica. 2004 Sep;34(9):847-59.
108 Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
109 Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
110 Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist J Clin Pharmacol. 2015 Sep;55(9):1004-11. doi: 10.1002/jcph.507.
111 Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
112 Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
113 Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34.
114 O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
115 Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
116 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
117 Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
118 FDA label:Avapritinib
119 Avapritinib: First Approval
120 Binimetinib Is a Potent Reversible and Time-Dependent Inhibitor of Cytochrome P450 1A2 Chem Res Toxicol. 2021 Apr 19;34(4):1169-1174. doi: 10.1021/acs.chemrestox.1c00036.
121 Product Monograph of Atacand.
122 Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
123 Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015 Apr-Jun;8(2):171-5.
124 N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
125 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
126 Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
127 Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004 Feb;308(2):495-501.
128 Functional characterization of human CYP2C9 allelic variants in COS-7 cells. Front Pharmacol. 2016 Apr 25;7:98.
129 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
130 DrugBank(Pharmacology-Metabolism):Ruxolitinib
131 Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
132 Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
133 PubChem:Tapinarof
134 Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007 Jul;35(7):1135-41.
135 Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos. 2001 Feb;29(2):141-4.
136 Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
137 In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
138 Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
139 Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma
140 Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
141 Lithium Intoxication in the Elderly: A Possible Interaction between Azilsartan, Fluvoxamine, and Lithium
142 Critical evaluation of the efficacy and tolerability of azilsartan
143 Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301.
144 Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
145 Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
146 Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
147 Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23.
148 Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):321-6.
149 Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10
150 Dataset of the first report of pharmacogenomics profiling in an outpatient spine setting
151 LABEL:DDYI- flibanserin tablet, film coated
152 Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
153 Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
154 Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.;
155 An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
156 Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr. 2009 Sep-Oct;9(5):133-4.
157 In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79.
158 Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases. Chem Res Toxicol. 2014 Dec 15;27(12):2071-81.
159 Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
160 Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87.
161 The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
162 Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 Apr;24(2):87-92.
163 Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
164 Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
165 Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
166 Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol. 1998 Mar 15;55(6):889-96.
167 In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
168 Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
169 FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
170 Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats
171 Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
172 FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
173 Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006 May;72(2):148-54.
174 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
175 FDA Label of Olodaterol. The 2020 official website of the U.S. Food and Drug Administration.
176 PubChem:Paramethadione
177 PubChem:Rimegepant
178 Effects of rimegepant 75?mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants
179 SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13. doi: 10.1002/dta.1645.
180 Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
181 In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 2000 May;56(2):135-40.
182 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
183 Population pharmacokinetic/pharmacodynamic analyses of avatrombopag in patients with chronic liver disease and optimal dose adjustment guide with concomitantly administered CYP3A and CYP2C9 inhibitors. J Clin Pharmacol. 2018 Dec;58(12):1629-1638.
184 Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
185 Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
186 Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450
187 FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
188 Umbralisib: First Approval
189 Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
190 Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk Eur J Intern Med. 2017 Jul;42:54-60. doi: 10.1016/j.ejim.2017.05.019.
191 Metabolism of 17 alpha-ethinylestradiol by human liver microsomes in vitro: aromatic hydroxylation and irreversible protein binding of metabolites J Clin Endocrinol Metab. 1974 Dec;39(6):1072-80. doi: 10.1210/jcem-39-6-1072.
192 The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
193 Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. Biomed Res Int. 2020 Aug 6;2020:1563874. doi: 10.1155/2020/1563874.
194 Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry. 2004 Jun 8;43(22):6948-58.
195 Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010 May;31(4):228-42.
196 Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
197 Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans
198 Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
199 No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine
200 Eurartesim - European Medicines Agency
201 In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
202 Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996 Aug;24(8):834-41.
203 Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
204 Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44.
205 Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep. 2019 Oct 31;9(1):15774.
206 Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
207 Effects of serum albumin and liver cytosol on CYP2C9- and CYP3A4-mediated drug metabolism. Drug Metab Pharmacokinet. 2002;17(6):522-31.
208 Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23(3-4):235-42.
209 Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Dispos. 2007 Apr;35(4):583-9.
210 CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
211 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
212 Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
213 Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019 Feb;176(3):466-477.
214 Product Monograph of Xtandi Rupatadine (as rupatadine fumarate).
215 CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004 Jul;76(1):18-26.
216 Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.
217 Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
218 Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. Eur J Clin Invest. 2009 Jun;39 Suppl 2:14-8.
219 Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
220 Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
221 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
222 Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens
223 Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects
224 Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
225 Australian Public Assessment Report for asunaprevir.
226 DrugBank(Pharmacology-Metabolism):Mavacamten
227 Studies on the metabolic fate of M17055, a novel diuretic (4): species difference in metabolic pathway and identification of human CYP isoform responsible for the metabolism of M17055
228 Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
229 Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814.
230 Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
231 Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
232 CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):99-108.
233 Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
234 S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes
235 In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
236 Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs
237 DrugBank(Pharmacology-Metabolism):TAK-491
238 DrugBank(Pharmacology-Metabolism):MRTX849
239 Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
240 DrugBank(Pharmacology-Metabolism):Ag-221
241 Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
242 Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
243 Lactobacillus rhamnosus induces CYP3A and changes the pharmacokinetics of verapamil in rats
244 In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
245 Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
246 Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke
247 Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans
248 Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism
249 Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2 Inhibitor PT2385 In Vivo and In Vitro
250 Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9
251 Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies
252 In vitro inhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight into in vitro and in vivo discrepancy of metabolite formation in humans
253 In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
254 Effect of deuteration on metabolism and clearance of Nerispirdine (HP184) and AVE5638
255 Metabolism and transport of oxazaphosphorines and the clinical implications Drug Metab Rev. 2005;37(4):611-703. doi: 10.1080/03602530500364023.
256 In vitro assessment of metabolic drugCdrug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
257 In vitro prediction and in vivo verification of enantioselective human tofisopam metabolite profiles
258 Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects
259 PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther. 2008 Jun;83(6):829-39.
260 Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D(2)/D(3) receptor antagonist for gastroparesis, towards cytochrome P450s and transporters
261 Metabolic map and bioactivation of the anti-tumour drug noscapine
262 Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
263 The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects
264 Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
265 In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification
266 Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species
267 Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
268 Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450-Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor
269 N-oxidation of irsogladine by the CYP2C subfamily in the rat, dog, monkey and man
270 A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer. 2015 Feb 17;112(4):650-9.
271 An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
272 Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans
273 [Investigation of metabolic kinetics and reaction phenotyping of ligustrazin by using liver microsomes and recombinant human enzymes]
274 Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells. Antimicrob Agents Chemother. 2005 May;49(5):2044-9. doi: 10.1128/AAC.49.5.2044-2049.2005.
275 Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor
276 Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog
277 Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers
278 Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica. 2000 Sep;30(9):905-14.
279 Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
280 Cytochrome P450 4A11 inhibition assays based on characterization of lauric acid metabolites
281 Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci. 2007 Dec;32(4-5):357-66.
282 Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes?
283 Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
284 High-performance liquid chromatographic determination of seratrodast and its metabolites in human serum and urine
285 DrugBank(Pharmacology-Metabolism)Aceclofenac
286 Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
287 Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
288 Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta. 2011 Jan;1814(1):210-22.
289 Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4.
290 LC-MS/MS determination of avanafil and its metabolites in rat plasma and brain: pharmacokinetic study after oral administration and transdermal film application
291 FDA:Avanafil
292 Identification of Epoxide-Derived Metabolite(s) of Benzbromarone
293 In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
294 Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
295 Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection Drug Metab Dispos. 2006 Mar;34(3):427-39. doi: 10.1124/dmd.105.007617.
296 Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922.
297 NORMAN Suspect List Exchange:Choline
298 Metabolic disposition of 14C-bromfenac in healthy male volunteers J Clin Pharmacol. 1998 Aug;38(8):744-52. doi: 10.1002/j.1552-4604.1998.tb04815.x.
299 In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
300 Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib Clin Pharmacokinet. 2017 May;56(5):477-491. doi: 10.1007/s40262-016-0461-9.
301 PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
302 Urine caffeine metabolites are positively associated with cognitive performance in older adults: An analysis of US National Health and Nutrition Examination Survey (NHANES) 2011 to 2014. Nutr Res. 2023 Jan;109:12-25. doi: 10.1016/j.nutres.2022.11.002.
303 Metabolism of carvedilol in dogs, rats, and mice Drug Metab Dispos. 1998 Oct;26(10):958-69.
304 Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8.
305 Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
306 DrugBank : Cinnarizine
307 Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.
308 Active cyamemazine metabolites in patients treated with cyamemazine (Tercian?): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET)
309 The KEGG resource for deciphering the genome
310 Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism
311 Dacomitinib: an investigational drug for the treatment of glioblastoma Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225.
312 LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):217-25. doi: 10.1016/j.jchromb.2004.09.040.
313 Classics in Chemical Neuroscience: Dextromethorphan (DXM). ACS Chem Neurosci. 2023 Jun 21;14(12):2256-2270. doi: 10.1021/acschemneuro.3c00088.
314 Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People Eur J Drug Metab Pharmacokinet. 2020 Aug;45(4):477-485. doi: 10.1007/s13318-020-00614-8.
315 Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants. Drugs R D. 2022 Mar;22(1):43-50. doi: 10.1007/s40268-021-00375-y.
316 Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. J Vet Pharmacol Ther. 2021 Sep;44(5):733-744. doi: 10.1111/jvp.12991.
317 DrugBank(Pharmacology-Metabolism)Diazepam
318 DrugBank(Pharmacology-Metabolism)Diclofenac sodium
319 Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis Eur J Clin Pharmacol. 1983;25(3):389-94. doi: 10.1007/BF01037953.
320 Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection J Chromatogr. 1981 Nov 6;217:263-71. doi: 10.1016/s0021-9673(00)88081-4.
321 Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls Clin Pharmacokinet. 1997 Sep;33(3):184-213. doi: 10.2165/00003088-199733030-00003.
322 Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
323 Bioconcentration, metabolism and effects of diphenhydramine on behavioral and biochemical markers in crucian carp (Carassius auratus) Sci Total Environ. 2016 Feb 15;544:400-9. doi: 10.1016/j.scitotenv.2015.11.132.
324 Non-invasive skin sampling detects systemically administered drugs in humans. PLoS One. 2022 Jul 26;17(7):e0271794. doi: 10.1371/journal.pone.0271794.
325 Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
326 Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids
327 Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions
328 Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
329 Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
330 FDA:Enasidenib
331 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
332 Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol Drug Metab Dispos. 2004 Nov;32(11):1299-303. doi: 10.1124/dmd.32.11..
333 Etodolac clinical pharmacokinetics
334 Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers
335 Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561-74.
336 In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510.
337 U. S. FDA Label -Fenfluramine
338 (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
339 Simultaneous identification and quantitation of fluoxetine and its metabolite, norfluoxetine, in biological samples by GC-MS
340 Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes
341 Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32.
342 Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669.
343 Diagnosis and subclassification of follicle center and mantle cell lymphomas on fine-needle aspirates: A cytologic and immunocytochemical approach based on the Revised European-American Lymphoma (REAL) classification Cancer. 1999 Aug 25;87(4):216-23.
344 Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation Drug Metab Dispos. 1999 Oct;27(10):1104-16.
345 Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon
346 Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
347 Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons
348 The metabolism of gliclazide in man
349 Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometry Arch Pharm Res. 2011 Dec;34(12):2073-8. doi: 10.1007/s12272-011-1210-0.
350 Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study J Pharm Biomed Anal. 2017 May 30;139:179-186. doi: 10.1016/j.jpba.2017.03.005.
351 U. S. FDA Label -Glipizide
352 Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human
353 DrugBank(Pharmacology-Metabolism): GV-150526 Tretazicar
354 Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism
355 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
356 In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1
357 Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans Biochem Pharmacol. 2013 Apr 15;85(8):1195-202. doi: 10.1016/j.bcp.2013.01.031.
358 Biotransformation of irbesartan in man Drug Metab Dispos. 1998 May;26(5):408-17.
359 PubChem : JNJ-54135419
360 The clinical toxicology of ketamine. Clin Toxicol (Phila). 2023 Jun;61(6):415-428. doi: 10.1080/15563650.2023.2212125.
361 Pharmacokinetics of Ketamine Transfer Into Human Milk. J Clin Psychopharmacol. 2023 May 23. doi: 10.1097/JCP.0000000000001711.
362 Chronic exposure to (2?R,6?R)-hydroxynorketamine induces developmental neurotoxicity in hESC-derived cerebral organoids. J Hazard Mater. 2023 Jul 5;453:131379. doi: 10.1016/j.jhazmat.2023.131379.
363 Characterization and quantification of metabolites of racemic ketoprofen excreted in urine following oral administration to man by 1H-NMR spectroscopy, directly coupled HPLC-MS and HPLC-NMR, and circular dichroism Xenobiotica. 2004 Nov-Dec;34(11-12):1075-89. doi: 10.1080/00498250412331281098.
364 Identification and structural characterization of in vivo metabolites of ketorolac using liquid chromatography electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) J Mass Spectrom. 2012 Jul;47(7):919-31. doi: 10.1002/jms.3043.
365 Label:KLH-2109
366 Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration Eur J Drug Metab Pharmacokinet. 2012 Dec;37(4):241-8. doi: 10.1007/s13318-012-0093-x.
367 Effect of the CYP2C9*3 allele on lornoxicam metabolism
368 In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
369 A prospective longitudinal study of growth in twin gestations compared with growth in singleton pregnancies. I. The fetal head J Ultrasound Med. 1991 Aug;10(8):439-43. doi: 10.7863/jum.1991.10.8.439.
370 Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13.
371 Quantification of mephenytoin and its metabolites 4'-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method
372 Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol
373 Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. J Clin Pharmacol. 1997 Mar;37(3):193-200.
374 Metamizole (Dipyrone) and the Liver: A Review of the Literature J Clin Pharmacol. 2019 Nov;59(11):1433-1442. doi: 10.1002/jcph.1512.
375 Clinical pharmacokinetics of dipyrone and its metabolites Clin Pharmacokinet. 1995 Mar;28(3):216-34. doi: 10.2165/00003088-199528030-00004.
376 Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
377 Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies
378 DrugBank(Pharmacology-Metabolism):Adagrasib
379 Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil J Cardiovasc Pharmacol. 1991 Dec;18(6):918-25. doi: 10.1097/00005344-199112000-00020.
380 Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
381 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
382 [Pharmacokinetics of phenazone after bilateral ovariectomy in female rabbits]
383 Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus
384 Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery
385 Disposition and biotransformation of the antiretroviral drug nevirapine in humans Drug Metab Dispos. 1999 Aug;27(8):895-901.
386 Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions J Antimicrob Chemother. 2014 Feb;69(2):476-82. doi: 10.1093/jac/dkt359.
387 Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. Biochem Pharmacol. 2022 Oct;204:115243. doi: 10.1016/j.bcp.2022.115243.
388 DrugBank(Pharmacology-Metabolism)Olodaterol hydrochloride
389 Paramethadione and metabolite serum levels in humans after a single oral paramethadione dose J Pharm Sci. 1975 Oct;64(10):1702-3. doi: 10.1002/jps.2600641027.
390 Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human Drug Metab Dispos. 2002 Sep;30(9):1013-21. doi: 10.1124/dmd.30.9.1013.
391 CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
392 The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
393 Anti-Parkinson's disease drugs and pharmacogenetic considerations Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):859-74. doi: 10.1517/17425255.2013.789018.
394 Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling
395 Validation of enantioseparation and quantitation of an active metabolite of abrocitinib in human plasma
396 The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans
397 Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men
398 The Analysis of Phenylbutazone and Its Active Metabolite, Oxyphenbutazone, in Equine Tissues (Muscle, Kidney, and Liver), Urine, and Serum by LC-MS/MS
399 McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 1999. Bethesda, MD:American Society of Health-System Pharmacists, Inc. 1999 (Plus Supplements)., p. 1760
400 In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants Cent Nerv Syst Agents Med Chem. 2017;17(3):172-177. doi: 10.2174/1871524917666161111093759.
401 Metabolism of piroxicam by laboratory animals Drug Metab Dispos. 1981 Mar-Apr;9(2):114-8.
402 Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41.
403 Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry Rapid Commun Mass Spectrom. 2007;21(2):169-79. doi: 10.1002/rcm.2813.
404 Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions. Pharmacol Rep. 2023 Apr;75(2):423-441. doi: 10.1007/s43440-023-00447-7.
405 Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of Prasugrel in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2023 Jan;12(1):21-29. doi: 10.1002/cpdd.1172.
406 Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice Drug Metab Dispos. 1998 Jun;26(6):585-94.
407 Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):255-64. doi: 10.1007/BF03190029.
408 Managing the Drug-Drug Interaction With Apixaban and Primidone: A Case Report. Hosp Pharm. 2023 Aug;58(4):345-349. doi: 10.1177/00185787221150928.
409 Ticagrelor and primidone interaction masquerading as dual antiplatelet therapy noncompliance. Future Cardiol. 2023 Jun 14. doi: 10.2217/fca-2023-0011.
410 In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
411 CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever
412 Netupitant PET imaging and ADME studies in humans
413 Biotransformation of moclobemide in humans
414 Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study
415 Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787.
416 The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers
417 Pharmacogenetic Testing and Therapeutic Drug Monitoring Of Sertraline at a Residential Treatment Center for Children and Adolescents: A Pilot Study. Innov Pharm. 2022 Dec 26;13(4):10.24926/iip.v13i4.5035. doi: 10.24926/iip.v13i4.5035.
418 Sertraline. 2022 May 15. Drugs and Lactation Database (LactMed?) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006C.
419 Neonicotinoids and pharmaceuticals in hair of the Red fox (Vulpes vulpes) from the Cavallino-Treporti peninsula, Italy. Environ Res. 2023 Jul 1;228:115837. doi: 10.1016/j.envres.2023.115837.
420 In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000 Apr;28(4):392-7.
421 Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
422 The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
423 Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x.
424 Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
425 Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
426 The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol. 1998 May;38(5):463-6.
427 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
428 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
429 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
430 Identification and biological activity of tamoxifen metabolites in human serum Biochem Pharmacol. 1983 Jul 1;32(13):2045-52. doi: 10.1016/0006-2952(83)90425-2.
431 PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.
432 LABEL:UCYNTA- tapentadol hydrochloride tablet, film coated
433 Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
434 Pharmacokinetics and metabolism of temazepam in man and several animal species Br J Clin Pharmacol. 1979;8(1):23S-29S. doi: 10.1111/j.1365-2125.1979.tb00451.x.
435 Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.
436 Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
437 The detection of piroxicam, tenoxicam and their metabolites in equine urine by electrospray ionisation ion trap mass spectrometry
438 Clinical pharmacokinetics of tenoxicam
439 Metabolism of tenoxicam in rats
440 Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
441 A multi-residue chiral liquid chromatography coupled with tandem mass spectrometry method for analysis of antifungal agents and their metabolites in aqueous environmental matrices. Anal Methods. 2021 Jun 14;13(22):2466-2477. doi: 10.1039/d1ay00556a.
442 Don't stay home without it
443 Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation
444 Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10
445 Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
446 Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography-electrochemical detection
447 Simultaneous determination of tranilast and metabolites in plasma and urine using high-performance liquid chromatography
448 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
449 Retinoic acid metabolism and mechanism of action: a review
450 LABEL:KLIEF- trifarotene cream
451 Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
452 Optimization via experimental design of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples J Sep Sci. 2006 Oct;29(15):2265-83. doi: 10.1002/jssc.200600093.
453 Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits J Cardiovasc Pharmacol. 2004 May;43(5):677-84. doi: 10.1097/00005344-200405000-00010.
454 Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes Xenobiotica. 2005 Jun;35(6):589-602. doi: 10.1080/00498250500158175.
455 Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996 Feb;41(2):149-56.
456 Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers
457 A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
458 Absorption, distribution, metabolism, and excretion of [1?C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening
459 Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor
460 Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
461 The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
462 Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
463 Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
464 FDA Approved Drug Products:Oxbryta (voxelotor) tablets
465 Metabolism and excretion of zafirlukast in dogs, rats, and mice
466 Metabolism and pharmacokinetics of the combination Zidovudine plus Lamivudine in the adult Erythrocebus patas monkey determined by liquid chromatography-tandem mass spectrometric analysis
467 Zolpidem urine excretion profiles and cross-reactivity with ELISA(?) kits in subjects using Zolpidem or Ambien(?) CR as a prescription sleep aid
468 Distribution of zopiclone and main metabolites in hair following a single dose

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.